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Cognitive impairments are a core feature of schizophrenia, and arise, in part, from deficits in 
gamma-amino butyric acid (GABA)-releasing neurons within the prefrontal cortex (PFC). ~30% 
of neurons in the PFC of schizophrenia have markedly reduced mRNA expression for the 67 kDa 
isoform of the GABA synthesizing enzyme, GAD67. Nearly all GABA neurons in primate 
neocortex can be classified into non-overlapping subtypes by expressing the calcium-binding 
proteins parvalbumin (PV), calbindin (CB), and calretinin (CR). About half of all PV neurons, 
which are subdivided into basket cells and chandelier cells, lack detectable GAD67 mRNA 
expression in schizophrenia. GAD67 protein levels are lower in axonal boutons from PV basket 
cells in PFC layers 3-4, and although GAD67 expression has not been assessed in chandelier 
cells they may also have lower GAD67 levels. Further, GAD67 expression has not been assessed 
in CB and CR neurons in the illness but correlative evidence suggests that they are differentially 
affected. For example, CB neurons coexpress somatostatin (SST) and in schizophrenia lower 
SST mRNA expression is correlated with lower GAD67 mRNA expression at both the tissue and 
cellular levels. By contrast, CR mRNA expression is unaltered and does not correlate with lower 
GAD67 mRNA expression. Therefore, lower GAD67 levels in schizophrenia are predicted to be 
restricted to PV and CB neurons, though this hypothesis has not been directly tested. 
Accordingly, we assessed GAD67 expression in chandelier, CB, and CR neurons in the PFC of 
schizophrenia and matched comparison subjects using quantitative confocal microscopy. This 
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required us to develop a novel technique to identify lipofuscin autofluorescence, which is 
prominent in human postmortem tissue. We found that the reported marked reduction in GAD67 
mRNA expression in only ~30% of neurons in schizophrenia is associated with markedly lower 
GAD67 protein levels in just a subset of axonal boutons. GAD67 protein levels were trending 
lower in chandelier cell boutons and were significantly lower in boutons from CB and CR 
neurons. Our findings suggest that a proportion of PV, CB, and CR neurons have lower GAD67 
expression in the PFC of schizophrenia subjects, which may be a consequence of a common 
mechanism, such as deficits in excitatory drive. 
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1.0  INTRODUCTION 
Schizophrenia is a devastating psychiatric illness with a worldwide prevalence of 0.5-1% (Lewis 
and Lieberman, 2000). Individuals with the illness typically come to clinical attention around late 
adolescence or early adulthood, and many suffer a lifetime of disability and emotional distress. 
Comorbid depression is commonly associated with the illness as well as nicotine, alcohol, and 
illicit drug use. Individuals with schizophrenia are overrepresented among the homeless, un- and 
under-employed, unmarried, and socially isolated, and many are on public assistance or are 
chronically hospitalized (Carpenter and Koenig, 2008). The lifespan of individuals with the 
illness are reduced by 1-2 decades, and 5-10% commit suicide (Auquier et al., 2007). As a result, 
schizophrenia can be a considerable financial and emotional burden for family members who are 
often the primary caretakers of individuals affected by the illness (Gibbons et al., 1984). In 
addition, schizophrenia incurs a substantial economic cost to society in terms of medical 
expenditures and lost productivity (Knapp et al., 2004; Wu et al., 2005).  
Schizophrenia manifests as a broad spectrum of dysfunctions in motor, perceptual, 
emotional, and cognitive processes that are classified into three symptom domains (Tandon et al., 
2009). The first domain is characterized by positive symptoms, which is generally described by 
the presence of extra perceptions and behaviors. These symptoms are the features of the illness 
commonly known as the “psychotic symptoms”, such as delusional ideation, the general belief 
that something exists in the absence of evidence for its existence; hallucinations, which may occur 
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in any sensory modality but are most commonly auditory (i.e. hearing voices that are distinct from 
one’s own); and abnormal psychomotor activity, such as disorganized behavior and abnormal 
posturing and/or rigid movements. The second symptom domain is negative symptoms or the 
absence of behaviors or emotions that are usually present. These arise from a lack of normal brain 
function and include social withdrawal and isolation, including from loved ones; avolition (lack 
of motivation and decision-making); alogia (deficiency in the amount and content of speech), and 
anhedonia (reduced capacity to experience pleasure). The third symptom domain encompasses 
cognitive deficits, which span multiple modalities including selective and sustained attention, 
working and episodic memory, executive and social function, and processing speed, suggesting an 
overall alteration in cognitive control (Green et al., 2004; Lesh et al., 2011). 
 Although positive symptoms are frequently the most striking feature of schizophrenia and 
bring individuals to clinical attention, cognitive impairments are recognized as the core feature of 
dysfunction (Kahn and Keefe, 2013). Cognitive performance, as measured by IQ tests or 
scholastic achievement, in youth aged 16 years or younger is inversely related to the risk of 
developing schizophrenia later in life (Dickson et al., 2012; MacCabe et al., 2008). Scholastic 
performance appears to significantly decline, with the most pronounced deficits in language 
skills, between 13 and 16 years of age in individuals who develop schizophrenia compared to 
their peers (Fuller et al., 2002); however poor cognitive performance may be evident as early as 7 
years of age and continue to lag throughout adolescence (Reichenberg et al., 2010). Moreover, a 
comparison of cognitive functioning in twins discordant for schizophrenia found evidence of 
impaired cognitive performance in the twin who developed the illness at 12 years of age, and 
these deficits preceded the first psychotic episode by many years (van Oel et al., 2002). 
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 Cognitive impairments occur throughout the lifespan of schizophrenia patients (Hedman 
et al., 2013), and may continue to decline after the onset of psychosis (Kahn and Keefe, 2013). 
The degree of cognitive dysfunction is the best predictor of long-term functional outcome and 
quality of life (Bowie et al., 2006; Green, 2006). Despite being the core feature of dysfunction, 
cognitive deficits in schizophrenia are relatively unaffected by current pharmacotherapy, which is 
almost entirely based on the administration of antipsychotic medication (Dold and Leucht, 2014). 
While these medications ameliorate positive symptoms associated with schizophrenia, they are no 
more effective than placebo or practice effects at improving cognitive impairments (Keefe et al., 
2008). The development of new treatments to improve cognition in schizophrenia subjects 
requires the identification of molecular targets based on their role in the pathophysiology of the 
illness (Insel and Scolnick, 2006). 
 The prefrontal cortex (PFC) is a brain region critically involved in cognitive processes 
(Miller and Cohen, 2001). Proper functioning of the PFC requires an intricate balance of 
excitation and inhibition that is provided by glutamate-releasing (glutamatergic) pyramidal 
neurons and gamma-aminobutyric acid (GABA)-releasing (GABAergic) neurons, respectively, 
both of which are altered in the PFC of schizophrenia subjects. This thesis directly assesses the 
extent of molecular alterations in specific subtypes of GABA neurons, which may be a 
consequence of glutamatergic deficits. In the following sections I will discuss the role of the PFC 
during cognitive processes and provide evidence for functional abnormalities in the PFC of 
schizophrenia subjects. I will then discuss the neuronal circuitry of the PFC and what is known 
about cellular and molecular deficits in schizophrenia, which will be used to guide hypotheses on 
alterations of specific GABA neuron subtypes in the illness. 
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1.1 COGNITIVE CONTROL DEFICITS IN SCHIZOPHRENIA: ROLE OF ALTERED 
PREFRONTAL CORTEX ACTIVITY 
1.1.1 Prefrontal cortex and cognitive control 
Cognitive control depends on the coordinated activity of several brain regions including the PFC 
(Braver et al., 1997; Cohen et al., 1997). The PFC receives afferent inputs from numerous brain 
regions and based on this connectivity pattern the PFC is thought to be critically important for the 
integration, active maintenance, and filtering of neural signals across several cognitive, sensory, 
and motor modalities (Miller and Cohen, 2001). Through the integration of widespread extrinsic 
and intrinsic neural signals from other brain regions the PFC selects information in order to guide 
appropriate cognitive responses based on these inputs (Asaad et al., 1998; Rainer et al., 1998; 
Watanabe, 1990). For example, performance on cognitive control tasks requiring working 
memory, which is the ability to integrate, temporarily maintain, and manipulate a limited amount 
of information in order to guide future thought or behavior, is critically dependent on PFC activity 
(Goldman-Rakic, 1995). Therefore, proper functioning of the PFC is integral for exerting top-
down control over a wide variety of behaviors that require cognitive control. 
1.1.2 Reduced prefrontal cortex activity in schizophrenia 
Functional imaging studies have established altered activity in the PFC of schizophrenia subjects. 
For example, studies measuring regional cerebral blood flow, which is thought to be positively 
correlated with neuronal activity, found reduced activity in the PFC of medication-naïve 
(Weinberger et al., 1988; Weinberger et al., 1986) and antipsychotic-treated (Berman et al., 1986) 
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subjects with schizophrenia while at rest and when performing tasks requiring working memory. 
Similarly, multiple studies measuring blood oxygen level dependent signal, an additional 
quantitative measure thought to reflect neuronal activity, show reduced activity in the PFC during 
cognitive control tasks (Glahn et al., 2005; Minzenberg et al., 2009; Perlstein et al., 2003). 
Moreover, cortical gamma-frequency oscillations are a signature of local neural processing 
thought to underlie higher order cognitive processes in humans (Fries, 2009). The power of 
gamma-frequency oscillations increases proportionally to the degree of difficulty of cognitive 
tasks (Howard et al., 2003; Roux et al., 2012). Subjects with schizophrenia exhibit impaired 
gamma-band power in the PFC and poor cognitive performance compared to non-psychiatric 
subjects (Cho et al., 2006; Minzenberg et al., 2010). 
 The integration and processing of neural signals required to generate strong activity within 
the PFC for proper cognitive functioning is critically dependent on the strong and synchronous 
firing of pyramidal cells (Goldman-Rakic, 1995) by GABA neurons (Constantinidis et al., 2002; 
Rao et al., 2000), which constitute ~75% and ~25%, respectively, of all neurons in monkey 
neocortex (Hendry et al., 1987). In schizophrenia, alterations in pyramidal cells and GABA 
neurons may contribute to reduced activity of the PFC and cognitive impairments. 
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1.2 EXCITATORY SIGNALING IN THE PREFRONTAL CORTEX: MARKED 
DEFICITS OF LAYER DEEP 3-4 PYRAMIDAL CELLS IN SCHIZOPHRENIA 
1.2.1 Extrinsic excitatory afferent projections 
Excitatory afferent projections between the PFC and other cortical regions are relayed 
predominantly via pyramidal cells in cortical layer 3, which principally target dendritic spines of 
pyramidal cells in layers 3-4 (Barbas and Rempel-Clower, 1997; Felleman and Van Essen, 1991). 
~80-90% of excitatory projections from pyramidal cells innervate dendritic spines of other 
pyramidal cells in distant brain regions and nearby, but distinct (e.g. projections from PFC area 46 
to PFC area 9), cortical areas (Medalla and Barbas, 2009; Melchitzky et al., 2001). Subcortical 
excitatory projections from the mediodorsal thalamic nuclei, which provide thalamic afferents to 
the PFC (Erickson and Lewis, 2004; Giguere and Goldman-Rakic, 1988; Goldman-Rakic and 
Porrino, 1985; Tobias, 1975), also predominantly target spines of pyramidal cells in layers 3-4 
(Giguere and Goldman-Rakic, 1988; Jones and Hendry, 1989). Thalamic projections constitute 
~10% of excitatory inputs to dendritic spines within these layer (Ahmed et al., 1994). 
1.2.2 Extrinsic excitatory afferent projections to GABA neurons 
Although layers deep 3-4 pyramidal cells are the recipients of the vast majority of thalamo-
cortical and cortico-cortical excitatory afferent projections, different brain regions preferentially 
innervate distinct subtypes of GABA neurons (Figure 1.1). Nearly all GABA neurons in primate 
PFC can be separated into non-overlapping subtypes by the expression of the calcium-binding 
proteins parvalbumin (PV), calbindin (CB), and calretinin (CR). Specifically, ~25%, ~20%, and 
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~45% of all GABA neurons express PV, CB, and CR, respectively (Conde et al., 1994; del Rio 
and DeFelipe, 1996; Gabbott and Bacon, 1996). In rat, thalamic afferents predominantly target 
PV neurons, and to a lesser extent CB and CR neurons (Rotaru et al., 2005). In monkey PFC, CB 
neurons are the predominant GABAergic subtype that receives projections from the anterior 
cingulate cortex (ACC) (Medalla and Barbas, 2009; Medalla and Barbas, 2010), suggesting that 
CB neurons in the PFC receive projections from brain regions responsible for distinct cognitive 
behaviors. For example, when performing a cognitive control task PFC area 9 shows greater 
activity during delay periods when subjects are maintaining information prior to making a 
response, which is consistent with the role of top-down control of the PFC (MacDonald et al., 
2000). By contrast, the ACC is more active during the response phase, suggesting that it has a 
strong role in performance monitoring. In monkey PFC, CR neurons are the predominant 
GABAergic subtype that receives projections from pyramidal cells in nearby brain areas, such as 
projections from area 46 to area 9 (Medalla and Barbas, 2009), which perform similar functions 
during working memory tasks (Levy and Goldman-Rakic, 1999; Petrides, 2000; Petrides et al., 
1993; Tanila et al., 1992; Tanji and Hoshi, 2008). 
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Figure 1.1. Schematic diagram of extrinsic excitatory projections from different brain regions to distinct 
neurons within PFC area 9. The thicker lines depict a greater percentage of innervations from the thalamus, anterior 
cingulate cortex (ACC), and PFC area 46 to the pyramidal cell (PYR) than to PV, CB, and CR neurons. 
 
 
 
 
1.2.3 Local excitatory afferent inputs 
Ultrastructural analyses in monkey PFC found that ~50% of local axon collaterals from 
supragranular pyramidal cells innervate the dendritic spines of local pyramidal cells, whereas the 
majority of the remaining inputs contact local PV neurons (Melchitzky et al., 2001; Melchitzky 
and Lewis, 2003). However, studies using transgenic mice to identify specific GABA neurons and 
glutamate uncaging to activate pyramidal cells across different layers of somatosensory cortex 
suggest that all GABA neurons receive local excitatory inputs but the laminar location of 
pyramidal cells providing those inputs differs for distinct GABA neurons (Xu and Callaway, 
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2009). For example, PV neurons in layers 2-3 receive stronger excitatory inputs from pyramidal 
cells around cortical layer 4 (Figure 1.2). By contrast CR-containing neurons in layers 2-3 
receive stronger excitatory inputs from pyramidal cells in layers 2-3. Moreover, in monkey PFC, 
> 80% of CR neurons express vasoactive intestinal peptide (VIP; ~80% of VIP neurons contain 
CR) (Gabbott and Bacon, 1997), and VIP-containing neurons in layers 2-3 of mouse 
somatosensory cortex receive the greatest strength of excitatory inputs from pyramidal cells in 
layers 2-3. CB neurons were not directly assessed; however, > 50% of CB neurons express 
somatostatin (SST), and ~85% of SST neurons contain CB (Gonchar and Burkhalter, 1997; 
Kubota et al., 1994; Rogers, 1992). Similar to PV cells, SST neurons generally receive greater 
excitatory drive from pyramidal cells around layer 4. 
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Figure 1.2. Schematic diagram of relative strength of excitatory drive from local pyramidal cells in different 
cortical layers to GABA neuron subtypes. The thicker lines from the pyramidal cells (PYR) depict greater strength 
of excitatory drive to PV, CB, and CR neurons. 
 
 
 
 
1.2.4 Deficits in layers deep 3-4 pyramidal cells 
Because cortico-cortical and thalamo-cortical afferent projections almost exclusively innervate 
dendritic spines of layer 3-4 pyramidal cells, spine density presumably reflects the amount of 
excitatory drive to these neurons and in general the PFC. Therefore, proper integration and 
processing of incoming neural signals critically depends on the integrity of layer 3-4 pyramidal 
cells. Several morphological alterations of pyramidal cells in PFC layers deep 3-4 are reported in 
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schizophrenia. These alterations include a lower density of dendritic spines (Glantz and Lewis, 
2000; Konopaske et al., 2014), reduction in the number and length of dendrites (Broadbelt et al., 
2002; Glantz and Lewis, 2000; Kalus et al., 2000), and smaller somal size (Pierri et al., 2001; 
Pierri et al., 2003; Rajkowska et al., 1998), which correlates with the extent of dendritic and 
axonal arborization in certain neuronal populations (Gilbert and Kelly, 1975; Hayes and Lewis, 
1993; Jacobs et al., 1997; Lund et al., 1975). Similar morphological alterations for deep layer 3 
pyramidal cells are also observed in other brain regions (Garey et al., 1998; Sweet et al., 2004; 
Sweet et al., 2009; Sweet et al., 2003) including the ACC (Broadbelt et al., 2002). By contrast, 
pyramidal cells located in other layers of the PFC do not appear to be as greatly affected by these 
alterations (Kolluri et al., 2005), suggesting that the deficits are specific to, or are at least more 
pronounced in, layers deep 3-4 pyramidal cells. The consistency that these morphological 
alterations are reported in the PFC and other brain regions suggest that they are a conserved 
feature of the illness. 
Multiple factors may contribute to the morphological deficits in deep layer 3 pyramidal 
cells in schizophrenia. For example, activity-dependent glutamate signaling can modify the 
structure and formation of dendrites and spines (Maletic-Savatic et al., 1999; McKinney et al., 
1999; Xie et al., 2005; Xie et al., 2007), and significant genome-wide variations in several loci 
associated with glutamate signaling are reported in schizophrenia (Schizophrenia Working Group 
of the Psychiatric Genomics, 2014). Total neuron number and volume of the mediodorsal 
thalamic nuclei and the number of putative thalamic projections to the PFC are lower in 
schizophrenia (Byne et al., 2001; Byne et al., 2002; Gilbert et al., 2001; Lewis et al., 2001; 
Pakkenberg, 1990; Popken et al., 2000; Young et al., 2000), which presumably results in reduced 
PFC activity; however, thalamic projections only account for a small proportion of glutamatergic 
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inputs to the cortex (Ahmed et al., 1994). Other sources of excitatory inputs to deep layer 3 
pyramidal cells such as intrinsic collaterals from other pyramidal cells or projections from other 
cortical regions, such as the ACC, may also contribute to lower PFC activity. Morphological 
deficits in layer 3 pyramidal cells of the ACC are reported in schizophrenia, and numerous 
functional imaging studies suggest that the activity of both the PFC and ACC is altered in 
schizophrenia patients during cognitive control tasks (Allen et al., 2007; Cho et al., 2006; Ikuta et 
al., 2012; Kerns et al., 2005; Minzenberg et al., 2010; Quintana et al., 2004; Schultz et al., 2012; 
Yucel et al., 2007). Alternatively, alterations for gene products that regulate cellular morphology, 
such as reduced expression for mRNAs that facilitate the formation and maintenance of spines, 
may reflect intrinsic deficits in spine structure (Hill et al., 2006; Ide and Lewis, 2010; Konopaske 
et al., 2015). Altered expression of proteins that regulate and maintain neuronal structure are also 
reported in the PFC of schizophrenia (Jones et al., 2002; Somenarain and Jones, 2010). Taken 
together, reduced number of excitatory inputs, reductions in the strength of glutamatergic 
signaling, intrinsic alterations in the transcription/translation of structural proteins, or a 
combination of these possibilities may contribute to reduced activity of layer deep 3-4 pyramidal 
cells in schizophrenia.  
 Considering that local excitatory afferents from layers deep 3-4 pyramidal cells 
preferentially innervate specific GABA neuron subtypes (Figure 1.2), it may be predicted that 
GABA neurons receiving the greatest strength of inputs from layers deep 3-4 pyramidal cells (i.e. 
PV and CB neurons) are also preferentially altered in schizophrenia. By contrast, GABA neurons 
that receive the greatest strength of inputs from pyramidal cells in other layers (i.e. CR neurons) 
may not be as greatly affected. 
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1.3 GABA NEURONS: REDUCED GAD67 EXPRESSION WITHIN A SUBSET OF 
NEURONS IN THE PREFRONTAL CORTEX OF SCHIZOPHRENIA 
1.3.1 Unique functional roles of GABA neuron subtypes in cortical networks 
1.3.1.a    PV neurons 
PV neurons can be subdivided into basket and chandelier cells. PV basket cells principally target 
the perisomatic region and proximal dendrites of pyramidal cells (Melchitzky et al., 1999), 
whereas chandelier cells exclusively innervate the axon initial segment (AIS) of pyramidal cells 
(Szentagothai and Arbib, 1974). By targeting the perisomatic region of pyramidal cells PV 
neurons exert strong control over their output (Glickfeld et al., 2009; Kato et al., 2013; Woodruff 
et al., 2011). Moreover, in vivo studies using optogenetic techniques to increase PV cell activity 
induce gamma-frequency oscillations in cortex (Cardin et al., 2009; Sohal et al., 2009), whereas 
genetic manipulations that decrease PV cell activity reduce hippocampal gamma synchrony in 
vitro and impair working memory performance (Fuchs et al., 2007). 
1.3.1.b    CB neurons 
CB is expressed in diverse subtypes of cortical GABA neurons and also pyramidal cells 
(DeFelipe et al., 1989; Freund et al., 1990; Gonzalez-Albo et al., 2001; Hayes and Lewis, 1992; 
Hof and Morrison, 1991). Much of what is known about the structure and function of GABAergic 
CB neurons comes from studying SST neurons, which is exclusively expressed by GABA 
neurons (Gonchar and Burkhalter, 2003; Gonzalez-Albo et al., 2001; Kubota et al., 1994; Sugino 
et al., 2006). SST neurons mainly target dendritic shafts and spines of pyramidal cells 
(Melchitzky and Lewis, 2008), whereby they regulate the integration of excitatory inputs within 
 14 
local cortical circuits (Kapfer et al., 2007; Lovett-Barron et al., 2012) and from thalamic afferents 
(Xu et al., 2013), and provide feedback inhibition in and between cortical layers (Wang et al., 
2004). Moreover, SST neurons provide a layer of tonic inhibition over the cortical network 
(Gentet et al., 2012), and suppressing the activity of SST neurons increases the overall excitability 
(i.e. gain) of pyramidal cells (Urban-Ciecko et al., 2015). 
1.3.1.c    CR neurons 
CR neurons mainly contact the dendrites and soma of GABA neurons (Melchitzky et al., 2005; 
Melchitzky and Lewis, 2008), whereby they mediate disinhibitory control of pyramidal cells. 
Much of what is known about the specific functions of CR neurons comes from studying VIP 
neurons using transgenic mouse models. These studies have strongly established that VIP neurons 
almost exclusively innervate other GABA neurons, many of which are SST and to a lesser extent 
PV neurons, and that this innervation pattern occurs across cortical and hippocampal regions 
(Donato et al., 2013; Fu et al., 2014; Kawaguchi Y, 1996; Lee et al., 2013; Neske et al., 2015; 
Pfeffer et al., 2013; Rogers, 1992; Staiger et al., 2004; Tyan et al., 2014). By mainly contacting 
GABA neurons CR/VIP neurons mediate selective amplification of local signal processing of 
pyramidal cells, which has been shown to be important for a number of sensory and cognitive 
processes (Donato et al., 2013; Fu et al., 2014; Lee et al., 2013; Pi et al., 2013). 
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1.3.2 Differential expression of the 65 kDa and 67 kDa isoforms of glutamic acid 
decarboxylase in GABA neuron subtypes 
The strength of signaling from GABA neurons is partially dependent on the amount of GABA 
available for synaptic release, which is synthesized within axonal boutons by the 65 kDa and 67 
kDa isoforms of the enzyme glutamic acid decarboxylase (GAD65 and GAD67, respectively). 
The majority of GABA neurons appear to express both GAD65 and GAD67 mRNAs, but a small 
proportion only expresses GAD67 mRNA. Specifically, ~20% of GABA neurons in monkey 
visual cortex are detectable by only GAD67 mRNA (Hendrickson et al., 1994), and GAD67-only 
mRNA expressing neurons are also evident in monkey PFC (Rocco et al., 2015). Moreover, 5-
10% of GABA neurons in CA1 and CA3 of rat hippocampus are detectable by mRNA for only 
GAD67 (Stone et al., 1999), suggesting that GAD67-only expressing neurons are present across 
brain regions and in different species. By contrast, no study to date has found evidence for GABA 
neurons that only express GAD65 mRNA. 
Neuronal differences in GAD65 and GAD67 mRNA expression are also evident at the 
protein level within axonal boutons. Out of all GABAergic boutons in monkey PFC, ~50% 
contain protein levels for both GAD65 and GAD67 (GAD65+/GAD67+), ~20% contain only 
GAD67 (GAD67+), and ~30% contain only GAD65 (GAD65+) (Rocco et al., 2015), which 
together with the mRNA findings suggests that GAD65+/GAD67+ and GAD65+ boutons arise 
from neurons expressing mRNAs for both GADs, whereas GAD67+ boutons arise from neurons 
expressing only GAD67 mRNA. Differences in the biophysical properties between the enzymes 
may explain why some boutons are GAD65+. For example, the half-life of GAD65 is > 24 hours, 
while that of GAD67 is ~2 hours (Battaglioli et al., 2003). 
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At the cell-type specific level all PV basket cell boutons appear to be GAD65+/GAD67+ 
and those from PV chandelier cells appear to all be GAD67+ (Fish et al., 2011; Glausier et al., 
2014). These findings appear to be recapitulated at the transcript level because two distinct 
subtypes of PV neurons are distinguishable by expressing mRNAs for both GADs and only 
GAD67, which are presumably basket and chandelier cells, respectively (Appendix A Figure 
A.1). CB and CR neurons give rise to GAD65+/GAD67+, GAD67+, and GAD65+ boutons. 
Consistent with the mRNA findings, the majority of CB and CR neurons express mRNAs for both 
GADs and a small proportion contain mRNA for only GAD67 (Rocco et al., 2015). Similar to CB 
and CR neurons, boutons from SST and VIP neurons give rise to GAD65+/GAD67+, GAD67+, 
and GAD65+ boutons (Rocco et al., 2015). 
1.3.3 GAD67 protein levels report on network activity 
Although GAD65 and GAD67 perform the same general function, they are products of separate 
genes (Erlander et al., 1991). Chronic reductions in network activity in rat cortical cultures lower 
GAD67 mRNA and protein levels, whereas GAD65 mRNA expression is less strongly associated 
with decreased GAD65 protein levels (Patz et al., 2003). Other studies have also shown that 
protein levels for both GAD65 and GAD67 are reduced under conditions of chronic network 
inactivity (Hartman et al., 2006; Lau and Murthy, 2012). By contrast, GAD67, but not GAD65, 
protein levels are reduced in response to acute increases in GABA levels (Rimvall and Martin, 
1994; Sheikh and Martin, 1998), suggesting that GAD67 is more strongly coupled to decreases in 
network activity. Differences in the half-life of the enzymes (i.e. > 24 hours and ~2 hours for 
GAD65 and GAD67, respectively) may explain why GAD67 is more transcriptionally regulated 
and more responsive to acute reductions in network activity compared to GAD65 (Huang, 2009). 
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1.3.4 Lower GAD67 expression in a subset of prefrontal cortex neurons in schizophrenia 
Perhaps the most widely and consistently reported finding in postmortem studies of subjects with 
schizophrenia is lower mRNA expression for GAD67 (Akbarian et al., 1995; Curley et al., 2011; 
Duncan et al., 2010; Guidotti et al., 2000; Hashimoto et al., 2003; Volk et al., 2000), which is 
accompanied by lower total GAD67 protein levels (Curley et al., 2011; Guidotti et al., 2000; 
Impagnatiello et al., 1998). Only ~30% of GABAergic neurons in schizophrenia PFC lack 
detectable levels of GAD67 mRNA, whereas the others express GAD67 mRNA at normal levels 
(Akbarian et al., 1995; Volk et al., 2000). The subset of GABAergic neurons with markedly lower 
GAD67 mRNA expression is prominent across PFC layers 2-5 (Akbarian et al., 1995; Volk et al., 
2000). This deficits occurs without a loss in total neuron density (Akbarian et al., 1995) or 
number (Thune et al., 2001), suggesting that all GABA neurons are present but that a subset have 
a markedly reduced capacity to synthesize GABA. A more recent study found that the density of 
neurons detectable by GAD67 mRNA was unchanged in schizophrenia (Guillozet-Bongaarts et 
al., 2014), supporting the idea that all GABA neurons are present but some have markedly low 
levels of GAD67 expression. By contrast, expression of other gene products involved in 
GABAergic neurotransmission is reported to be unaffected or only modestly altered in the PFC of 
schizophrenia subjects. For example, mRNA and protein levels for GAD65 are unchanged 
(Guidotti et al., 2000; Hashimoto et al., 2008; Impagnatiello et al., 1998), as well as the density of 
GAD65-immunoreactive (IR) puncta (Benes et al., 2000); however, GAD65 mRNA and protein 
levels may be preferentially lower in the PFC of subjects diagnosed with schizoaffective disorder 
(Glausier et al., 2015). Moreover, mRNA for the vesicular GABA transporter (vGAT), which 
packages GABA into synaptic vesicles, was reported to be unchanged or only modestly lower in 
the PFC of schizophrenia subjects (Fung et al., 2011; Hoftman et al., 2013). 
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Roughly 1/3 of the ~30% of neurons with markedly reduced GAD67 mRNA expression 
are comprised of PV neurons. Specifically, ~50% of all PV neurons, which are ~25% of all 
GABA neurons, lack detectable levels of GAD67 mRNA expression across all PFC layers in 
schizophrenia subjects (Hashimoto et al., 2003); though, this study did not differentiate between 
PV basket and chandelier cells. A more recent study that used a small cohort of schizophrenia and 
matched non-psychiatric comparison subjects to quantify protein levels in PV basket cell boutons 
found that GAD67 protein levels were ~50% lower in PFC layers 3-4 in the illness (Curley et al., 
2011), which suggests that at least some PV basket cells are affected with marked reductions in 
GAD67 expression. Convergent findings suggest that PV chandelier cells may also be affected by 
marked reductions in GAD67 expression. For example, the convergence of multiple chandelier 
cell boutons at the AIS appears as a distinctive structure termed a cartridge (Lewis and Lund, 
1990), which can be visualized with multiple markers involved in GABA signaling including PV 
and the GABA transporter, GAT1 (DeFelipe and del Carmen Gonzalez-Albo, 1998; DeFelipe et 
al., 1989). In schizophrenia, the density of GAT1-IR cartridges is reduced by 40% across PFC 
layers 2-6 (Pierri et al., 1999; Woo et al., 1998). By contrast, the density of AISs visualized by 
immunoreactivity for the α2 subunit of the GABA A receptor is 2-fold greater in PFC layers 2-
superficial 3 (Volk et al., 2002). These pre- and post-synaptic alterations are speculated to be 
compensatory for deficits in GABA signaling that may result from reduced GAD67 protein levels 
in PV chandelier cell boutons because lower GAT1 levels would presumably increase the latency 
of post-synaptic responses upon GABA release (Overstreet and Westbrook, 2003), and the up-
regulation of GABA A receptors at the AIS would increase the efficacy of GABA binding. 
However, GAD67 levels have not been assessed in PV chandelier cell boutons in schizophrenia. 
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Therefore, whether PV basket and chandelier cells are similarly affected by marked reductions in 
GAD67 expression or if one subtype is preferentially affected is unknown. 
 Considering that PV neurons only constitute ~1/3 of the neurons that lack detectable 
GAD67 mRNA expression in schizophrenia, CB and/or CR neurons must have lower GAD67 
expression levels; however, these subtypes may be differentially affected in the illness. For 
example, > 50% of CB neurons express somatostatin (SST), and ~85% of SST neurons contain 
CB (Gonchar and Burkhalter, 1997; Kubota et al., 1994; Rogers, 1992). Deficits in SST mRNA 
expression are widely reported in the PFC of schizophrenia subjects (Fung et al., 2010; Gabriel et 
al., 1996; Hashimoto et al., 2008; Hashimoto et al., 2008; Mellios et al., 2009; Morris et al., 
2008). Both the density of SST mRNA-positive neurons and levels of SST mRNA per neuron are 
lower across PFC layers 2-superficial 6 (Morris et al., 2008). Moreover, lower SST mRNA 
expression correlates with lower GAD67 mRNA expression at both the tissue and cellular levels 
(Hashimoto et al., 2008; Morris et al., 2008), which suggests that at least some CB neurons give 
rise to boutons with reduced GAD67 protein levels. By contrast, CR mRNA and total protein 
expression, as well as the density of CR-IR boutons are unaltered (Fung et al., 2010; Hashimoto et 
al., 2008; Hashimoto et al., 2003; Woo et al., 1998). CR mRNA levels do not correlate with lower 
GAD67 mRNA levels in the illness (Hashimoto et al., 2008), suggesting that CR neurons are 
relatively unaltered. Since CB neurons constitute ~20% of all GABA neurons, the ~30% of 
GABA neurons with markedly reduced GAD67 mRNA levels may be comprised of PV and CB 
neurons, which are the subtypes that receive high levels of excitatory inputs from pyramidal cells 
exhibiting the greatest signaling deficits in schizophrenia (i.e. pyramidal cells in layers deep 3-4). 
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1.3.5 Potential mechanisms for lower GAD67 expression in schizophrenia 
The cause(s) of lower GAD67 expression in the PFC of schizophrenia is unclear because the 
deficit occurs across multiple layers and it is unknown if only specific subtypes of GABA neurons 
are affected or if a proportion of several different neurons are affected. The previous convergent 
findings suggesting that PV and SST neurons, but not CR neurons, have marked deficits in 
GAD67 expression is consistent with our prediction that the GABA neuron subtypes that receive 
the greatest strength of excitatory drive from layers deep 3-4 pyramidal cells (Figure 1.2) exhibit 
the greatest activity-dependent alterations (i.e. lower GAD67 expression) in schizophrenia. 
Therefore, we hypothesize that GAD67 levels are markedly reduced in PV and CB, but not CR, 
neurons (Figure 1.3). 
Alternatively, multiple other mechanisms may contribute to lower GAD67 expression. For 
example, allelic variants in the gene encoding GAD67, GAD1, are associated with lower GAD67 
expression levels and an increased risk of schizophrenia (Addington et al., 2005; Straub et al., 
2007). Dysregulated epigenetic mechanisms, such as altered chromatin-associated histone 
modifications and higher-order chromatin structure at the GAD1 promoter region are also 
associated with lower GAD67 expression in the illness (Bharadwaj et al., 2013; Huang et al., 
2007; Tang et al., 2011). Reduced mRNA expression for upstream regulatory factors of the GAD1 
gene have been reported in schizophrenia and correlate with reduced levels of GAD67 mRNA 
(Kimoto et al., 2014). However, along with previous findings, our findings suggest that the subset 
of GABA neurons with markedly lower GAD67 expression is comprised of a proportion of 
several subtypes of GABA neurons, and none of these alternative factors provide an obvious 
mechanism that could account for lower GAD67 expression in just a subset of neurons. 
 
 21 
 
 
 
 
Figure 1.3. Schematic diagram of predicted GAD67 expression alterations in GABA neuron subtypes in 
response to reduced excitatory drive from layer deep 3-4 pyramidal cells. The asterisk indicates GAD67 protein 
level findings in boutons from PV basket cells (PVb) in PFC layers 3-4 of schizophrenia (Curley et al., 2011). 
GAD67 expression levels have not been directly assessed in PV chandelier (PVch), CB, and CR neurons in the 
illness. The thicker lines from the pyramidal cell (PYR) depict greater strength of excitatory drive to PV, CB, and CR 
neurons. 
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1.4 GOALS OF THIS DISSERTATION 
Cognitive impairments are a core feature of schizophrenia and are, in part, a result of 
glutamatergic and GABAergic deficits in the PFC. Only ~30% of neurons in the PFC lack 
detectable GAD67 mRNA expression. The overall goal of this dissertation is to determine if 
chandelier cells, CB neurons, or CR neurons are preferentially affected by markedly reduced 
GAD67 expression or if a proportion of each subtype is affected. Development of novel methods 
to unbiasedly detect protein level changes in human postmortem tissue using quantitative multi-
label fluorescence confocal microscopy techniques (2.0) was required to first ask how well the 
prior reported deficits in GAD67 mRNA levels in schizophrenia translate to GAD67 protein 
levels within axonal boutons, the site of vesicular GABA release (3.0). Consistent with the 
mRNA findings, we found that only a subset of boutons had markedly reduced GAD67 protein 
levels, which led us to assess GAD67 protein levels in boutons from chandelier cells (4.0), and 
CB and CR neurons (5.0) in the PFC of schizophrenia subjects. Gaining insight into which of 
these subtypes is affected is important for understanding potential causal effects of a GAD67 
deficit in schizophrenia. 
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2.0  QUANTITATIVE METHODS TO ASSESS PROTEIN LEVELS IN AXONAL 
BOUTONS IN POSTMORTEM HUMAN TISSUE USING FLUORESCENCE 
CONFOCAL MICROSCOPY TECHNIQUES 
2.1 INTRODUCTION 
A quantitative method to unbiasedly assess the colocalization of multiple synaptic proteins within 
axonal boutons in postmortem human tissue using fluorescence confocal microscopy techniques 
is described in the following section. These methods are a detailed description of the human 
subjects cohort and the procedures used to assess bouton protein levels between matched pairs of 
schizophrenia and comparison subjects in 3.0, 4.0, and 5.0. 
2.2 HUMAN SUBJECTS COHORT 
2.2.1 Brain collection 
Brain specimens were recovered during autopsies conducted at the Allegheny County Medical 
Examiner’s Office (Pittsburgh, PA, USA) after obtaining consent from the next of kin. The left 
hemisphere of each brain was blocked coronally at 1-2 cm intervals, immersed in ice cold 4% 
paraformaldehyde for 48 hours and then washed in a series of graded sucrose solutions and 
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cryoprotected in a 30% glycerol/ 30% ethylene glycol solution at -30ºC until sectioned. Tissue 
blocks containing PFC area 9 were sectioned coronally at 40 µm on a cryostat and stored in 
cryoprotectant solution at -30ºC until processed for immunohistochemistry. The University of 
Pittsburgh’s Committee for the Oversight of Research Involving the Dead and Institutional 
Review Board for Biomedical Research approved all procedures. 
2.2.2 Subject pairing 
An independent committee of experienced research clinicians made consensus DSM-IV 
diagnoses for each subject using the results of structured interviews conducted with family 
members and/or review of medical records (Hashimoto et al., 2008). To reduce biological 
variance between diagnostic groups, and to control for experimental variance, each schizophrenia 
subject was matched to one comparison subject with no known history of neurological or 
psychiatric disorder (N= 20 pairs) perfectly for sex, and as closely as possible for PMI, age, and 
time stored in cryoprotectant solution at -30ºC (Table 2.1). The rate of protein degradation, which 
begins at death, varies between different proteins (Beneyto et al., 2008; Curley et al., 2011). In 
contrast to RNA studies using postmortem human tissue, in which the RNA integrity number (i.e. 
RIN) can be used as a quantitative measure of RNA degradation, there is currently no equivalent 
quantitative measure for protein degradation. Also, aging can differentially affect gene expression 
(Hoftman et al., 2013). To reduce the effects of these confounding variables we selected all 
available schizophrenia subjects from the Brain Tissue Donation Program at the University of 
Pittsburgh with PMI < 16 hours and age ≤ 55 years (Appendix B Table B.1). Importantly, an 
independent samples t-test found that there were no diagnostic group differences in PMI, age, or 
freezer storage time. 
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Table 2.1. Summary of demographic and postmortem characteristics of human subjects. There were no 
diagnostic group differences in age (t38 = 0.276, p = 0.784), postmortem interval (t38 = 0.327, p = 0.745), or freezer 
storage time (t38 = 0.268, p = 0.790). 
 
 
 
 
 
 
2.3 EXPERIMENTAL METHODS 
2.3.1 Experimental design 
For each subject (N=40), four sections containing PFC area 9 spaced ~500 µm apart were used. 
To minimize experimental variance within and across subject pairs, two separate 
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immunohistochemistry runs consisting of two sections per subject (80 sections total per run) were 
performed with all sections within a run processed simultaneously. The only difference between 
runs was that antibodies against CB and CR were used in Run #1 and Run #2, respectively, all 
other antibodies were the same (Table 2.2). 
 
 
 
 
Table 2.2. Experimental design and list of primary antibodies. 
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u
n
 #
1
R
u
n
 #
2
CB
vGAT
GAD65
GAD67
CR
vGAT
GAD65
GAD67
Species Antigen Dilution Source Chapter
Rabbit
Mouse
Guinea pig
Goat
Rabbit
Mouse
Guinea pig
Goat
1:1000
1:500
1:500
1:100
1:1000
1:500
1:500
1:100
Swant
# CB-38a
Lot: 9.03
Synaptic Systems
# 131011
Lot: 131011/41
Synaptic Systems
# 198104
Lot: 198104/3
R&D Systems
# AF2086
Lot: KRD0110031
Swant
# 7699/4
Lot: 18_3_13
Synaptic Systems
# 131011
Lot: 131011/42
Synaptic Systems
# 198104
Lot: 198104/4
R&D Systems
# AF2086
Lot: KRD0110031
3, 4, 5
3, 4, 5
4, 5
5
3, 4, 5
3, 4, 5
4, 5
5
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2.3.2 Immunohistochemistry 
The antigenicity of some synaptic proteins is reduced in postmortem human tissue. For example, 
the detection of vGAT immunoreactivity in postmortem human tissue requires antigen retrieval 
procedures, which is a method that improves antigenicity (Jiao et al., 1999) (Figure 2.1). 
Importantly, the detection of GAD65, GAD67, CB, and CR are not affected by the antigen 
retrieval method used here. Accordingly, before the sections were immunolabeled they were 
incubated in 0.01M sodium citrate in distilled H2O at 80ºC for 75 minutes (Jiao et al., 1999), 
cooled to room temperature (RT), and then rinsed with 0.1M phosphate buffer (PB). 
 
 
 
 
 
Figure 2.1. Antigen retrieval and vGAT detection in postmortem human tissue. Single plane images from a 
perfusion-fixed monkey PFC tissue section (A) and immersion-fixed human PFC tissue sections from the same 
human subject that were immunolabeled for vGAT (B and C). No antigen retrieval was performed on A and B, but C 
did receive antigen retrieval. The tissue section in B and C were immunolabeled simultaneously, imaged using the 
same exposure setting, and the histogram settings for the images are identical. Bar = 10 μm. 
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Next, the sections were incubated in 1% sodium borohydride in PB for 30 minutes at RT 
to reduce autofluorescence due to aldehyde fixation and then rinsed in 0.1M phosphate buffered 
saline (PBS). The sections were permeabilized with 0.3% Triton X-100 in PBS for 30 minutes at 
RT, incubated in 20% donkey serum in PBS for 2 hours at RT, and then incubated for ~72 hours 
at 4ºC in PBS containing 2% donkey serum and primary antibodies (Table 2.2). Antibody 
specificity was verified in our laboratory or other laboratories (vGAT (Guo et al., 2009); GAD65 
and GAD67 (Fish et al., 2011)). Sections were then rinsed for 2 hours in PBS and incubated for 
24 hours in PBS containing 2% donkey serum and secondary antibodies (donkey host) conjugated 
to Alexa Fluor 405 (CB or CR), Alexa Fluor 488 (vGAT), Cy 3 (GAD65) or Alexa Fluor 647 
(GAD67) at 4ºC. All Alexa Fluor dyes were from Invitrogen (Grand Island, NY, USA; 1:500 for 
all) and Cy 3 was from Fitzgerald (Acton, MA, USA; 1:500). After washing, sections were 
mounted (ProLong Gold antifade reagent, Invitrogen) on slides, which were coded to blind 
diagnosis and subject number, and stored at 4ºC until imaged. Secondary antibody specificity was 
verified by omitting the primary antibody in control experiments. Multiple pilot studies were 
performed to determine if any primary/secondary combinations influenced the outcome; results 
from these studies indicated that the ability to detect each antigen was not dependent on the 
secondary antibody spectra. 
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2.4 DATA COLLECTION 
2.4.1 Microscopy equipment 
Data were collected on an Olympus (Center Valley, PA) IX81 inverted microscope equipped with 
an Olympus spinning disk confocal unit, Hamamatsu EM-CCD digital camera (Bridgewater, NJ), 
and high precision BioPrecision2 XYZ motorized stage with linear XYZ encoders (Ludl 
Electronic Products Ltd., Hawthorne NJ) using a 60X 1.40 N.A. SC oil immersion objective. The 
equipment was controlled by SlideBook 5.0 (Intelligent Imaging Innovations, Inc., Denver, CO, 
USA), which was the same software used for post-image processing. 
2.4.2 Image acquisition 
3D image stacks (2D images successively captured at intervals separated by 0.25 µm in the z-
dimension) that were 512 x 512 pixels (~137 x 137 µm) were acquired over 50% of the total 
thickness of the tissue section starting at the coverslip. Importantly, imaging the same percentage 
of the tissue section thickness rather than a constant depth controls for the potential confound of 
storage and/or mounting related volume differences (e.g. z-axis shrinkage). 
 Over- or under-exposing fluorescently labeled images can greatly influence the quality of 
the acquired data as well as confound the results. For example, over-exposing tissue sections may 
result in images with saturated pixels, which create a ceiling effect for intensity measurements. 
Alternatively, under-exposing tissue sections may yield images where only the brightest objects 
are detectable, which may bias the number of IR objects assessed. The latter scenario is 
particularly important when measuring protein levels that may be reduced in disease states. 
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Examples of things in brain tissue that can greatly influence exposure settings include artifacts 
introduced during experimental procedures, variability of protein content in distinct IR neuronal 
structures, a high density of unlabeled cell bodies, blood vessels, and autofluorescence from 
lipofuscin, which is a lipoprotein byproduct of lysosomal degradation that accumulates with 
senescence and is prominent in postmortem human brain tissue (Brody, 1960). 
Over- or under-exposing fluorescently labeled images occur at a higher frequency when 
using constant exposure settings rather than optimal exposure settings (i.e., those that yield the 
greatest dynamic range with no saturated pixels). Therefore, to reduce the effects of confounds 
caused by exposure settings each image stack was collected using optimal exposure settings for 
each immunofluorescent channel, with differences in exposures normalized during image 
processing. TetraSpeck microspheres (fluorescent blue/green/orange/dark red; Invitrogen) were 
used to confirm the absence of alignment issues between wavelengths of each channel. 
2.4.3 Novel method for detecting lipofuscin autofluorescence  
Lipofuscin autofluorescence can greatly influence exposure settings during image acquisition, but 
it is also a potential confound for quantitative measures, such as fluorescence intensity and object 
density analyses. Because of its broad spectral properties lipofuscin autofluorescence may be 
detected across all of the fluorescent wavelengths used to detect our immunolabeled antigens. In 
general, signal from lipofuscin autofluorescence is most robust when the signal of the 
immunolabeled antigens is relatively low. By contrast, lipofuscin autofluorescence may be 
undetectable when the signal of the immunolabeled antigens is relatively high. Previous 
immunofluorescent experiments in postmortem human tissue detected lipofuscin autofluorescence 
by immunolabeling fewer antigens and using a standard excitation/emission filter setting (i.e. the 
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filter setting used to detect Alexa Fluor 405 immunolabeled antigens) to detect lipofuscin (Curley 
et al., 2011; Glausier et al., 2014). However, we took advantage of lipofuscin’s broad spectral 
properties, and were able to detect lipofuscin autofluorescence via stokes shift using the excitation 
and emission filter settings that are typically used for detecting Alexa Fluor 405 and 647, 
respectively (Figure 2.2). These specific filter settings were used because they yielded robust 
lipofuscin autofluorescence signal without detecting any signal from immunolabeled antigens 
across all secondary antibody spectra. This approach yielded an additional channel, which was 
used to detect lipofuscin autofluorescence, without sacrificing a fluorescent channel that was used 
to detect our immunolabeled antigens (Figure 2.3). Since lipofuscin autofluorescence is relatively 
consistent within and across subjects compared to immunoreactive fluorescence signal, and 
because its fluorescence intensity levels and volume do not differ between pairs of schizophrenia 
and age-matched comparison subjects (Curley et al., 2011; Glausier et al., 2015), we used a 
constant exposure setting to detect lipofuscin autofluorescence. 
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Figure 2.2. Custom filter setting to detect lipofuscin. (A-E) Projection image (5 z-planes taken 0.25 μm) of an 
unlabeled human tissue section showing the excitation (ex) and emission (em) wavelengths obtained using the Sedat 
Quad 89000 filter set (Chroma Technology; Bellow Falls, VT, USA) that were used to detect lipofuscin 
autofluorescence. (A-D) Standard filter settings used to detect (A) Alexa Fluor 405, (B) Alexa Fluor 488, (C) Cy 3, 
and (D) Alexa Fluor 647. (E) Excitation and emission filter settings from A and D, respectively. Bar = 10 μm. 
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Figure 2.3. Lipofuscin detection in immunolabeled tissue. (A-F) Projection image (10 z-planes taken 0.25 μm) of a 
human PFC tissue section immunolabeled for CB, vGAT, GAD65, and GAD67. Detection of the single channel 
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images for (A) CB, (B) vGAT, (C) GAD65, (D) GAD67, and (E) Lipofuscin were performed using the filter settings 
specified in Figure 2.2 panels A, B, C, D, and E, respectively. (F) Merged image of A, C, and D. Bar = 10 μm. 
 
 
 
 
2.4.4 Sampling 
As determined by measurements made in Nissl stained sections of human PFC (Pierri et al., 
1999), the boundaries of the six cortical layers, defined by cytoarchitectonic criteria, in area 9 can 
be precisely estimated based on the distance from the pial surface to the gray/white matter border. 
For sampling the total gray matter of the PFC, we divided the cortical mantle into layers as 
follows: layer 1 (pia-10%), layer 2-superficial 3 (10-35%), layer deep 3/ 4 (35-60%), layer 5 (60-
80%), and layer 6 (80%-gray/white matter border) (Figure 2.4). Ten, systematic randomly 
sampled image stacks were taken within each of these subdivisions using a sampling grid of 180 x 
180 µm
2
. Running means using pilot data indicated that 10 sites per subdivision were sufficient to 
limit intra-subject variability for intensity and density measures. The same investigator (BRR), 
who was blind to subject and diagnosis, collected a total of 8,000 image stacks (1,600 stacks per 
layer). Importantly, subjects within a pair were imaged on the same day. 
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Figure 2.4. Layer delineation for sampling within total PFC gray matter. Nissl stained monkey PFC tissue 
section showing layer delineation by cytoarchitectonic criteria (Roman numerals) and by layer 1 (L1), layer 
2/superficial 3 (L2/3s), layer deep 3/4 (L3d/4), layer 5 (L5), and layer 6 (L6), which correspond to 0-10%, 10-35%, 
35-60%, 60-80%, and 80-100%, respectively, of the total gray matter area spanning from pia to the gray/white matter 
border. Bar = 250 μm. 
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2.5 DATA SEGMENTATION 
2.5.1 Image processing 
Each channel used to detect immunoreactivity was deconvolved using AutoQuant’s Blind 
Deconvolution algorithm (MediaCybernetics; Rockville, MD, USA). No processing was 
performed on the channel used to detect lipofuscin autofluorescence. 
 For data segmentation, a Gaussian channel was made for each fluorescent channel by 
calculating a difference of Gaussians using sigma values of 0.7 and 2. This was done to improve 
the ability to discriminate between non-overlapping immunoreactive puncta (Figure 2.5). 
Importantly, the Gaussian channel was used for data segmentation only. 
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Figure 2.5. Method to improve discrimination of non-overlapping puncta. To improve data segmentation, a 
Gaussian channel was made for each deconvolved channel by calculating a difference of Gaussians using sigma 
values of 0.7 and 2, which improves the ability to discriminate puncta. (A) Image of a 100 nm diameter fluorescent 
microsphere processed as labeled and shown in x,y-axis (top) and x,z-axis (bottom). Autoquant = deconvolved 
images; σ = Gaussian blur radius; line plots = intensity profile of a line drawn through the center of the microsphere; 
Bar = 2 μm. Note: after subtracting the Gaussian channels, negative pixel values were converted to zero. (B) 
Projection image (3 z-planes separated by 0.20 μm) of a GAD65-IR puncta (open arrowhead) and a GAD67-IR 
puncta (solid arrowhead). Bar = 0.5 μm. (C) Line intensity plots (dotted line within the inset image) of GAD65 (red 
line) and GAD67 (green line) fluorescent intensity levels in the apposed GAD65-IR and GAD67-IR puncta from B. 
Shaded plots represent the line intensities after Gaussian subtraction. The dashed lines show the boundaries of 
GAD65 (red) and GAD67 (green) object masks made using the Autoquant deconvolved Gaussian subtracted channel 
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and the iterative approach described in 2.5.2. Red and green arrowheads show the boundaries of the GAD65 and 
GAD67 masks, respectively, made using the Autoquant channel prior to Gaussian subtraction. Importantly, the 
Gaussian subtracted channel is used for data segmentation only; fluorescence intensity levels are calculated from the 
Autoquant deconvolved channels. 
 
 
 
 
2.5.2 Masking immunoreactive objects 
Data segmentation was performed as described (Fish et al., 2008), with a few exceptions. A single 
optimal threshold value, which incorporated the Ridler-Calvard iterative thresholding algorithm 
(Ridler and Calvard, 1978) and also accounted for variance in fluorescence intensity between sites 
was used to obtain an initial value for iterative segmentation for each channel within each image 
stack. Multiple iterations with subsequent threshold settings increasing by 25 gray levels were 
performed in MATLAB R2012 (MathWorks; Natick, MA, USA). After each iteration, the object 
masks were size-gated within a range of 0.03-0.5 µm
3
.  
The lipofuscin channel was masked using a single optimal threshold value for each image 
stack, and each lipofuscin mask was size-gated so that all were ≥ 0.03 µm3. Any CB, CR, vGAT, 
GAD65, and GAD67 object masks that overlapped a lipofuscin mask were eliminated from 
analyses. A paired analysis of covariance (ANCOVA) model, which included the sum 
fluorescence intensity of lipofuscin as the dependent measure, diagnostic group as the main effect, 
subject pair as the blocking factor, and tissue storage time as a covariate, and an unpaired 
ANCOVA which included age, PMI, and storage time as covariates found no differences in 
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lipofuscin fluorescence intensity between schizophrenia (648 ± 140 a.u.) and comparison (656 ± 
147 a.u.) subjects (paired F1, 19 = 0.08, p = 0.79; unpaired F1, 36 = 0.03, p = 0.86). 
2.6 DATA ANALYSES 
2.6.1 Virtual cropping 
For analyses, the image stacks were virtually cropped in the x-, y-, and z-dimensions. This was 
done using the center x-, y-, and z-coordinates of the IR puncta object masks. In the x- and y-
dimensions the center of each object mask had to be contained in the central 490 x 490 pixels of 
the image. To select the z-dimension used for analyses, the z-position of each object mask was 
normalized by the following equation: 
Zcoordinate (# of z-planes for image stack / 40) 
Next, each object mask was placed in one of 40 z-bins based on its normalized z-position. 
The mean object mask density and mean fluorescence intensity for CB, CR, vGAT, GAD65, and 
GAD67 were determined within each z-bin, and used for an analysis of variance with post-hoc 
comparison via Tukey’s honestly significant difference test. The maximum number of adjacent z-
bins that were not significantly different for both intensity and object mask number across all 
channels were used for analyses (n = 17 bins, which corresponded to 8.5 µm of the cut tissue 
thickness). By taking this approach we controlled for possible edge effects (i.e. all puncta 
assessed were fully represented in the virtual space), differences in antibody penetration, and 
differences in fluorochromes. The final object masks were then used to collect information on the 
deconvolved channels. 
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2.6.2 Method for defining colocalization 
All vGAT-IR puncta were considered to be boutons (vGAT+ boutons)(Chaudhry et al., 1998; 
McIntire et al., 1997). vGAT+ boutons that contained GAD immunoreactivity were classified as 
containing detectable levels of GAD65 and low to no GAD67 levels (vGAT+/GAD65+ boutons), 
low to no GAD65 levels and detectable levels of GAD67 (vGAT+/GAD67+ boutons), and 
detectable levels of both GADs (vGAT+/GAD65+/GAD67+ boutons). Initially to obtain the 
vGAT+/GAD+ bouton subpopulations, mask operations, which assess the degree of overlap 
between voxels of distinct object masks, were used to identify GAD65 and vGAT object masks 
that overlapped each other’s centers and did not overlap a GAD67 object mask (vGAT+/GAD65+ 
boutons). vGAT+/GAD67+ boutons were similarly defined. vGAT object masks that overlapped 
the center of both a GAD65 and GAD67 object mask were defined as 
vGAT+/GAD65+/GAD67+. Figure 2.6 illustrates the accuracy of defining boutons as GAD65-
IR, GAD67-IR, or GAD65-IR/GAD67-IR using only mask operations. 
 41 
 
 
Figure 2.6. GAD content in boutons that were defined using only mask operations. Example showing the use of 
mask operations to assess colocalization of GAD65-IR and GAD67-IR puncta. (A-I) Projection images (3 z-planes 
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taken 0.20 μm apart) of a monkey PFC tissue section immunolabeled for GAD65 and GAD67. Single GAD65 (A) 
and GAD67 (D) channels. Corresponding GAD65 (B) and GAD67 (E) object masks. Overlay of GAD65 and GAD67 
channels with their corresponding object masks (C and F, respectively). (G) Merged GAD65 and GAD67 channels. 
(H) Merged GAD65 and GAD67 object masks. (I) The image in G overlaid with those object masks in H that are 
colocalized (yellow), which designate GAD65+/GAD67+ boutons. Arrows depict putative GAD65+ boutons (open 
arrowheads), GAD67+ boutons (solid arrowheads), and GAD65+/GAD67+ boutons (arrows). Bar = 10 μm. 
 
 
 
 
Next, intensity information from the boutons defined by using mask operations was used 
to define the remaining vGAT+ boutons. Specifically, the mean fluorescence intensity of GAD65 
for all vGAT+/GAD65+ and vGAT+/GAD65+/GAD67+ boutons and the mean fluorescence 
intensity of GAD67 for all vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ boutons that were 
classified using mask operations criteria were used as seeds in a K-means cluster analysis to 
classify all boutons per each image stack. Figure 2.7 shows scatterplots from a single randomly 
chosen stack for each step of the method used to classify boutons as vGAT+/GAD65+, 
vGAT+/GAD67+, and vGAT+/GAD65+/GAD67+. 
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Figure 2.7. Classification of GAD content in vGAT+ boutons. (A-D) Mean GAD65 and GAD67 fluorescence 
intensities from individual vGAT+ boutons from a randomly selected image stack of monkey PFC immunolabeled for 
vGAT, GAD65, and GAD67. Each vGAT+ bouton was classified as vGAT+/GAD65+, vGAT+/GAD67+, or 
vGAT+/GAD65+/GAD67+ using mask operations and K-means cluster analysis. (A) Scatterplot of mean GAD65 
and GAD67 fluorescence intensities of all vGAT object masks that overlapped a GAD65 and/or GAD67 object mask. 
(B) Mask operations was used to select vGAT object masks in A that overlapped the center of a GAD65 object mask 
and did not overlap a GAD67 object mask (red; vGAT+/GAD65+ boutons), that overlapped the center of a GAD67 
object mask and did not overlap a GAD65 object mask (green; vGAT+/GAD67+ boutons), or that overlapped the 
center of a single GAD65 and a single GAD67 object mask (yellow; vGAT+/GAD65+/GAD67+ boutons). 
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vGAT+/GAD+ boutons classified by only mask operations accounted for ~70% of all vGAT+ boutons that were 
GAD-IR. (C) vGAT object masks in A that did not meet the mask operations classification criteria used in B. (D) All 
vGAT object masks in A classified using the mean GAD65 and GAD67 fluorescence intensity values calculated from 
the three vGAT+/GAD+ bouton subpopulations in B as seeds in a K-means cluster analysis. Black data points were 
vGAT object masks that did not meet criteria to be classified as vGAT+/GAD65+, vGAT+/GAD67+, or 
vGAT+/GAD65+/GAD67+ boutons using these criteria. 
 
 
 
 
2.7 CONCLUSION 
The methodology used here is an unbiased quantitative approach to assess bouton protein levels 
via the colocalization of multiple pre-synaptic proteins in postmortem human tissue. Every step of 
the method was meant to reduce the effects of confounding variables inherent in human tissue and 
in studies using fluorescence confocal microscopy. This Chapter is a detailed description of the 
methods that were used to quantify bouton density and bouton protein levels in 3.0, 4.0, and 5.0 
between matched pairs of schizophrenia and comparison subjects. 
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3.0  MARKEDLY LOWER GAD67 PROTEIN LEVELS IN A SUBSET OF BOUTONS 
IN THE PREFRONTAL CORTEX OF SCHIZOPHRENIA 
Adapted from: Rocco BR, Lewis DA, Fish KN. Markedly lower glutamic acid decarboxylase 67 
protein levels in a subset of boutons in schizophrenia. Submitted April 22, 2015 to Biological 
Psychiatry 
3.1 INTRODUCTION 
Cognitive deficits, such as impairments in working memory, are recognized as core clinical 
features in schizophrenia (Kahn and Keefe, 2013), and these impairments are thought to reflect, at 
least in part, disturbances in GABA neurons within the PFC (Lewis, 2014). Perhaps the most 
widely and consistently reported finding in postmortem studies of schizophrenia subjects is lower 
levels of mRNA for GAD67 (Akbarian et al., 1995; Curley et al., 2011; Duncan et al., 2010; 
Guidotti et al., 2000; Hashimoto et al., 2003; Volk et al., 2000). Although less well-studied, the 
deficit in GAD67 mRNA has been reported to be accompanied by lower GAD67 protein levels 
(Curley et al., 2011; Guidotti et al., 2000; Impagnatiello et al., 1998). The consistency of these 
findings suggests that lower GAD67 expression in schizophrenia is a common feature of the 
illness. Other findings indicate that it is not a consequence of illness chronicity or other factors 
frequently associated with the illness, such as use of antipsychotic medications (Curley et al., 
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2011; Hoftman et al., 2013). 
However, not all GABA neurons exhibit lower GAD67 mRNA expression in 
schizophrenia. Specifically, ~30% of GABA neurons in schizophrenia PFC lack detectable levels 
of GAD67 mRNA, whereas the others express GAD67 mRNA at normal levels (Akbarian et al., 
1995; Volk et al., 2000). The subset of GABA neurons with markedly lower GAD67 mRNA 
expression is prominent in PFC layers 2-5 (Akbarian et al., 1995; Volk et al., 2000). This deficit 
occurs in the absence of a change in total neuron density (Akbarian et al., 1995) or number 
(Thune et al., 2001), suggesting that all GABA neurons are present but that a subset have a 
markedly reduced capacity to synthesize GABA. Moreover, expression of some other gene 
products that can affect GABAergic neurotransmission are reported to be unaffected or only 
slightly altered in schizophrenia. For example, mRNA for vGAT is reported to be unchanged or 
only modestly lower in the PFC of schizophrenia subjects (Fung et al., 2011; Hoftman et al., 
2013), suggesting that the ability to load GABA into vesicles is preserved in the illness. 
Although the timing of onset of the GAD67 mRNA deficit is unknown, dysfunction of the 
PFC in schizophrenia appears to be a late developmental event. For example, in children who are 
later diagnosed with schizophrenia, working memory performance appears to be intact until about 
9 years of age and then subsequently declines (Reichenberg et al., 2010). Because working 
memory relies on the coordinated firing of PFC pyramidal neurons (Goldman-Rakic, 1995) by 
GABA neurons (Constantinidis et al., 2002; Rao et al., 2000), these findings suggest that the 
GAD67 deficit may arise during childhood. Knowing if structural alterations in GABAergic 
axonal boutons occur in schizophrenia could inform on the timing of the GAD67 deficit in the 
illness. For example, genetic reduction of GAD67 expression in PV basket cells during early 
stages of development results in fewer boutons, whereas the same reduction later does not alter 
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axonal architecture (Chattopadhyaya et al., 2007). Thus, it would be expected that a reduction in 
GAD67 expression during the pre- or peri-natal periods in individuals who are later diagnosed 
with schizophrenia would be accompanied by fewer GABAergic boutons. 
In concert, these findings suggest the following testable hypotheses: 1) The density of all 
GABAergic boutons is unaltered in the PFC of subjects with schizophrenia; 2) GAD67 protein 
levels are markedly lower in a subset of these boutons.  
3.2 MATERIALS AND METHODS 
3.2.1 Experimental procedures 
Specific procedures for tissue procurement, subject pairing, immunohistochemistry, and data 
collection and segmentation are described in 2.0. Briefly, PFC tissue sections from 20 pairs of 
schizophrenia and matched comparison subjects (Table 2.1) were immunolabeled for vGAT and 
GAD67 (Table 2.2). Bouton density and relative fluorescence intensity levels of vGAT and 
GAD67 within boutons were assessed within total gray matter using quantitative confocal 
microscopy techniques. 
3.2.2 Definitions of vGAT+ and vGAT+/GAD67-IR boutons 
All vGAT- IR puncta were considered to be GABAergic boutons (vGAT+ boutons)(Chaudhry et 
al., 1998; McIntire et al., 1997). vGAT+ boutons were classified as being IR for GAD67 
(vGAT+/GAD67-IR boutons) as follows: initially, mask operations were used to identify vGAT 
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and GAD67 object masks that overlapped each other’s centers as described in 2.6.2. Next, for 
each site the mean fluorescence intensity of GAD67 for all boutons identified in the first step 
were used as seeds in a K-means cluster analysis to classify vGAT+ boutons as being GAD67-IR. 
An example of boutons classified as vGAT+ and vGAT+/GAD67-IR is shown in Figure 3.1. 
 
 
 
 
 
Figure 3.1. vGAT and GAD67 colocalization in human postmortem tissue. (A-H) Projection image (5 z-planes 
separated by 0.25 µm) of a human PFC tissue section immunolabeled for vGAT and GAD67. Single GAD67 (A) and 
vGAT (B) IR channels, and single channel of lipofuscin (C) autofluorescence. (D) Merged GAD67, vGAT, and 
lipofuscin channels. Single GAD67, vGAT, and lipofuscin channels overlaid with their corresponding object masks 
(E, F, and G, respectively). Importantly, the object masks in F define the vGAT+ boutons (green object masks). (H) 
Single vGAT channel overlaid with vGAT object masks from F that were defined as vGAT+/GAD67-IR boutons 
(yellow object masks). Bar = 5 µm. 
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3.2.3 Statistics 
Data are presented as mean bouton density (± standard deviation; SD) and mean sum fluorescence 
intensity (± SD). Two analyses of covariance (ANCOVA) models were used to analyze the 
bouton density and protein level data. Because subjects were selected and processed as pairs, the 
first paired ANCOVA model included bouton density or protein level as the dependent variable, 
diagnostic group as the main effect, subject pair as a blocking factor, and tissue storage time as a 
covariate. Subject pairing is an attempt to balance diagnostic groups for sex, age, and PMI, and to 
account for the parallel processing of tissue samples, and thus is not a true statistical paired 
design. Consequently, a second unpaired ANCOVA model was performed that included age, 
PMI, and storage time as covariates. All statistical tests were conducted with α-level= 0.05. 
We also assessed the potential influence of other factors that are frequently comorbid with 
the diagnosis of schizophrenia using ANCOVA models. For these analyses, we compared 
subjects with schizophrenia using each variable (sex; diagnosis of schizoaffective disorder; use of 
nicotine at the time of death (ATOD), antipsychotics ATOD, antidepressants ATOD, or 
benzodiazepines and/or sodium valproate ATOD) as the main effect and age, tissue storage time, 
and PMI as covariates. A Bonferroni-adjusted α-level of 0.05/6 = 0.008 was used to assess 
significance. 
Reported ANCOVA statistics include only those covariates that were statistically 
significant. As a result, the reported degrees of freedom vary across analyses. 
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3.3 RESULTS 
3.3.1 vGAT+ bouton density and vGAT protein levels are unchanged in schizophrenia 
A total of 968,186 ± 82,032 and 948,895 ± 95,695 vGAT+ boutons for each schizophrenia and 
comparison subject, respectively, were analyzed. The density of vGAT+ boutons did not differ 
(paired F1, 19 = 0.69, p = 0.417; unpaired F1, 38 = 0.47, p = 0.497) between diagnostic groups 
(schizophrenia: 0.033 ± 0.003 boutons/µm
3
; comparison: 0.032 ± 0.003 boutons/µm
3
; Figure 
3.2A). Also, bouton levels of vGAT protein did not differ (paired F1, 19 = 3.34, p = 0.083; 
unpaired F1, 38 = 3.64, p = 0.064) between diagnostic groups (schizophrenia: 564 ± 72 a.u.; 611 ± 
83 a.u.; Figure 3.2B). 
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Figure 3.2. vGAT+ bouton densities and vGAT protein levels. Mean vGAT+ bouton density (A) and bouton 
vGAT protein levels (B) in total gray matter. The data points in each scatterplot represent a matched pair of 
schizophrenia (sz) and comparison (cntl) subject. Points below the unity line reflect pairs in which the measures are 
lower for the schizophrenia relative to the comparison subject. 
 
 
 
 
3.3.2 vGAT+/GAD67-IR bouton density is lower in schizophrenia 
The density of vGAT+/GAD67-IR boutons was 16% lower (paired F1, 19 = 10.39, p = 0.004; 
unpaired F1, 38 = 12.44, p = 0.001) in schizophrenia (0.015 ± 0.003 boutons/µm
3
) relative to 
comparison (0.018 ± 0.002 boutons/µm
3
) subjects (Figure 3.3A). These findings suggest that a 
subset of vGAT+ boutons lack detectable GAD67 protein levels. 
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3.3.3 vGAT+/GAD67-IR bouton GAD67 protein levels are lower in schizophrenia 
vGAT protein levels in vGAT+/GAD67-IR boutons did not differ (paired F1, 18 = 0.16, p = 0.69; 
unpaired F1, 37 = 0.06, p = 0.81) between diagnostic groups (schizophrenia: 822 ± 134 a.u.; 
comparison: 817 ± 122 a.u.; Appendix C Figure C.1). By contrast, GAD67 protein levels in 
vGAT+/GAD67-IR boutons were 14% lower (paired F1, 19 = 9.57, p = 0.006; unpaired F1, 38 = 
8.33, p = 0.006) in schizophrenia (808 ± 120 a.u.) relative to comparison (942 ± 172 a.u.) subjects 
(Figure 3.3B). To assess if lower GAD67 levels were present in all vGAT+/GAD67-IR boutons 
in subjects with schizophrenia, GAD67 levels per bouton in the comparison group were divided 
into 10 equally spaced bins and each bouton from both subject groups was placed into a bin based 
on its GAD67 level (Figure 3.3C). The presence of boutons in the bin corresponding to the upper 
10th percentile suggests that some boutons do not have a reduction in GAD67 levels. 
 
 
 
 53 
 
 
Figure 3.3. vGAT+/GAD67-IR bouton densities and GAD67 protein levels. Mean bouton density (A) and GAD67 
protein levels per vGAT+/GAD67-IR bouton (B) in total gray matter. (C) To assess if GAD67 levels were 14% lower 
across all boutons in schizophrenia, the range of GAD67 levels in the comparison group was used to make 10 equally 
separated bins and each bouton from both diagnostic groups was placed into a bin based on its GAD67 level. 
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3.3.4 Lower vGAT+/GAD67-IR bouton density and GAD67 protein levels are not 
attributable to comorbid factors 
GAD67 protein levels in vGAT+/GAD67-IR boutons, and the density of vGAT+/GAD67-IR 
boutons did not differ as a function of sex, nicotine use ATOD, benzodiazepines and/or sodium 
valproate ATOD, antidepressants ATOD, antipsychotics ATOD, or diagnosis of schizoaffective 
disorder (Figure 3.4). 
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Figure 3.4. Effects of comorbid factors on vGAT+/GAD67-IR bouton density and levels of GAD67 in subjects 
with schizophrenia. ATOD, at time of death; benz/val; benzodiazepines/valproic acid; SAD, schizoaffective 
disorder. 
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3.4 DISCUSSION 
In schizophrenia neither neuronal density (Akbarian et al., 1995) nor total neuron number (Thune 
et al., 2001) are altered in the PFC, suggesting that all GABA neurons are present. In support of 
this interpretation, others have found no difference in the density of GAD65-IR puncta in the PFC 
of subjects with schizophrenia relative to comparison subjects (Benes et al., 2000). However, in 
primate PFC not all boutons contain detectable levels of GAD65 (Fish et al., 2011; Glausier et al., 
2014; Rocco et al., 2015). Here, the presence of vGAT, which is required to package GABA for 
vesicular release (Chaudhry et al., 1998), and therefore is a marker of all GABAergic terminals, 
was used to quantify GABAergic bouton density. Importantly, vGAT mRNA levels (Fung et al., 
2011; Hoftman et al., 2015) are not altered in schizophrenia. We found no differences in the 
density of vGAT+ boutons between schizophrenia and comparison subjects in the PFC. In 
concert, these findings support the hypothesis that the density of GABAergic axonal boutons is 
unaltered in the PFC of subjects with schizophrenia. 
Convergent findings suggest that in addition to its role as the primary inhibitory 
neurotransmitter in the adult brain, GABA signaling is crucial for the maturation of inhibitory 
synapses (Huang, 2009). For example, genetic knockdown of GAD67 in developing GABA 
neurons results in a cell-autonomous reduction in bouton formation (Chattopadhyaya et al., 2007). 
By contrast, reduced GAD67 expression in mature GABA neurons does not alter bouton number 
or morphology. Thus, the observations made here of markedly lower bouton GAD67 levels but a 
normal complement of vGAT boutons suggests that the GAD67 deficit in schizophrenia occurs 
after the maturation of the affected GABA neurons. Interestingly, in monkey PFC mature levels 
of vGAT and GAD67 mRNA are not achieved until the peripubertal period (Hoftman et al., 
2013). This interpretation is supported by the finding that in schizophrenia working memory 
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performance appears to be intact prior to 9 years of age, but slowly declines afterwards 
(Reichenberg et al., 2010), suggesting that GAD67 levels within PFC GABA neurons involved in 
working memory are reduced later in development. 
At the cellular level, the density of GABA neurons with detectable levels of GAD67 
mRNA is ~30% lower across cortical layers 2-5 in the PFC of subjects with schizophrenia, 
whereas the levels of GAD67 mRNA within the other neurons do not differ from healthy 
comparison subjects (Akbarian et al., 1995; Volk et al., 2000). These findings led us to 
hypothesize that GAD67 protein levels are markedly lower in a subset of boutons. Our finding 
that GAD67 protein levels are markedly lower in 16% of GABAergic boutons such that they are 
no longer detectable by GAD67 immunoreactivity supports this hypothesis. However, considering 
that ~30% of GABA neurons are affected by marked deficits in GAD67 mRNA expression it was 
surprising that GAD67 levels were not markedly lower in more boutons. We did find that mean 
GAD67 levels were 14% lower in the remaining vGAT+/GAD67-IR boutons. This finding could 
reflect a general 14% reduction in vGAT+/GAD67-IR bouton GAD67 levels, but some boutons 
appear to have normal levels of GAD67 protein (Figure 3.3C), suggesting that a subset of 
boutons have lower, but still detectable GAD67 levels. The idea that the capacity to synthesize 
GABA is impaired in a subset of GABAergic boutons is in accordance with evidence that GAD67 
mRNA is lower only in a subset of GABA neurons. PV neurons appear to be affected by 
markedly reduced GAD67 mRNA expression (Hashimoto et al., 2003), and GAD67 levels have 
been reported to be lower in boutons of PV basket cells (Curley et al., 2011). 
The cause(s) of lower PFC GAD67 levels in schizophrenia is unclear but multiple 
mechanisms may contribute to the deficit. For example, allelic variants in the gene encoding 
GAD67, GAD1, are associated with lower GAD67 expression and an increased risk of 
 58 
schizophrenia (Addington et al., 2005; Straub et al., 2007). Dysregulated epigenetic mechanisms, 
such as altered chromatin-associated histone modifications and higher-order chromatin structure 
at the GAD1 promoter region are also associated with lower GAD67 expression in the illness 
(Bharadwaj et al., 2013; Huang et al., 2007; Tang et al., 2011). Reduced mRNA expression for 
upstream regulatory factors of the GAD1 gene have been reported in schizophrenia and correlate 
with reduced levels of GAD67 mRNA (Kimoto et al., 2014). However, none of these factors 
provide an obvious mechanism to account for lower GAD67 mRNA in just a subset of GABA 
neurons and lower GAD67 protein in just a subset of boutons. Alternatively, lower GAD67 
expression may be a compensatory response to lower activity in cortical pyramidal neurons 
(Lewis et al., 2012) in which case those GABA neurons that receive high levels of excitatory 
drive from pyramidal neurons, such as PV neurons (Melchitzky and Lewis, 2003), might be 
predicted to be preferentially affected. The fact that the number of excitatory inputs to the affected 
pyramidal neurons is reduced during late childhood and adolescence (Petanjek et al., 2011) might 
account for the late developmental reduction in GAD67 predicted by the results of the present 
study. 
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4.0  GAD67 PROTEIN LEVELS ARE UNCHANGED IN CHANDELIER CELL 
BOUTONS IN THE PREFRONTAL CORTEX OF SCHIZOPHRENIA 
4.1 INTRODUCTION 
~30% of neurons in the PFC of schizophrenia subjects lack detectable GAD67 mRNA expression 
(Akbarian et al., 1995; Volk et al., 2000), which is associated with a lack of detectable GAD67 
protein levels in 16% of vGAT+ boutons, and a 14% reduction in GAD67 levels in boutons with 
detectable GAD67 immunoreactivity (3.0). These deficits occur without a change in neuronal 
density or number (Akbarian et al., 1995; Thune et al., 2001) and bouton density (3.0). Several 
findings suggest that reduced GAD67 expression affects multiple subtypes of GABA neurons 
(Curley et al., 2011; Fung et al., 2010; Morris et al., 2008; Woo et al., 1998), and therefore 
identifying which GABA neuron subtypes are affected by lower GAD67 levels is important for 
understanding the potential causes of a GAD67 deficit in schizophrenia. 
 PV neurons contribute to the subset of GABA neurons with marked reductions in GAD67 
expression. Specifically, roughly half of all PV neurons lack detectable levels of GAD67 mRNA 
in the PFC of schizophrenia (Hashimoto et al., 2003). PV neurons can be subdivided into basket 
cells and chandelier cells based on morphological and molecular properties. For example, PV 
basket cells principally target the perisomatic region and proximal dendrites of pyramidal cells 
(Melchitzky et al., 1999), whereas chandelier cells exclusively innervate the AIS of pyramidal 
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cells (Szentagothai and Arbib, 1974). Moreover, boutons from PV basket cells are 
GAD65+/GAD67+, whereas those from chandelier cells are GAD67+ (Fish et al., 2011; Glausier 
et al., 2014). In schizophrenia, GAD67 protein levels are ~50% lower in PV basket cell boutons in 
PFC layers 3-4 (Curley et al., 2011), suggesting that at least some PV basket cells have reductions 
in GAD67 expression.  
 GAD67 levels have not been assessed in PV chandelier cells in schizophrenia; however 
convergent findings suggest that GAD67 levels may be lower in their boutons. The convergence 
of multiple chandelier cell boutons at the AIS appears as a distinctive structure termed a cartridge 
(Lewis and Lund, 1990), which can be visualized with multiple markers involved in GABA 
signaling including PV, vGAT, and the GABA transporter, GAT1 (DeFelipe and del Carmen 
Gonzalez-Albo, 1998; DeFelipe et al., 1989; Fish et al., 2013). In schizophrenia, the density of 
GAT1-IR cartridges is reduced by 40% across PFC layers 2-6 (Pierri et al., 1999; Woo et al., 
1998). By contrast, the density of AISs visualized by immunoreactivity for the α2 subunit of the 
GABA A receptor is 2-fold greater in PFC layers 2-superficial 3 (Volk et al., 2002). These pre- 
and post-synaptic alterations are hypothesized to be compensatory for deficits in GABA signaling 
that may result from reduced GAD67 protein levels in PV chandelier cell boutons (Lewis, 2011) 
because lower GAT1 levels would presumably increase the latency of post-synaptic responses 
upon GABA release (Overstreet and Westbrook, 2003), and the up-regulation of GABA A 
receptors at the AIS would increase the efficacy of GABA binding. Together, these findings led 
us to hypothesize that GAD67 protein levels are markedly lower in chandelier cell boutons in the 
PFC of schizophrenia subjects 
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4.2 MATERIALS AND METHODS 
4.2.1 Experimental Procedures 
Specific procedures for tissue procurement, subject pairing, immunohistochemistry, and data 
collection and segmentation are described in 2.0. Briefly, PFC tissue sections from 20 pairs of 
schizophrenia and matched comparison subjects (Table 2.1) were immunolabeled for vGAT, 
GAD65, and GAD67 (Table 2.2). Sections immunolabeled in Run #1 were used to assess 
measures of cartridge density and relative vGAT and GAD67 fluorescence intensity levels within 
cartridge boutons across PFC layers 2-6 using quantitative confocal microscopy techniques. 
Secondary measures of bouton density and relative vGAT and GAD67 fluorescence intensity 
levels within boutons were assessed in PFC total gray matter using Run #1 and #2. 
4.2.2 Definition of cartridges and vGAT+ cartridge boutons 
Cartridges were identified in layers 2/3s, 3d/4, 5, and 6 by their distinctive structure using vGAT 
immunoreactivity (Figure 4.1). Within each field, an unbiased counting frame (~68 x 68 µm
2
) 
consisting of two exclusion lines and two inclusion lines placed over the image stack was used to 
identify potential vGAT-IR cartridges for analysis. vGAT-IR cartridges were included for 
analysis and manually traced only if they were considered to be completely visualized as 
indicated by (1) continuity across z-planes; (2) the entire cartridge was contained within a virtual 
sampling box. The sampling box started and ended one z-plane from the top and bottom of the 
image stack, respectively, and had x-y start/end coordinates that were located 20 pixels from any 
edge. The entire structure of every vGAT-IR cartridge that met these criteria was manually 
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masked (Figure 4.1G). vGAT object masks that overlapped a cartridge mask were considered to 
be vGAT+ cartridge boutons (Figure 4.1H). 
 Secondary analyses were performed using vGAT+ boutons that were IR for GAD67 only 
(vGAT+/GAD67+) or GAD65 and GAD67 (vGAT+/GAD65+/GAD67+), which were classified 
using a multistep process. Initially, mask operations were used to identify vGAT and GAD65 or 
GAD67 object masks that overlapped each other’s centers. vGAT+/GAD67+, and 
vGAT+/GAD65+/GAD67+ boutons that did not meet the mask operations criteria were classified 
by GAD65 and GAD67 fluorescence intensity as described in 2.6.2. Examples of boutons 
classified as vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ are shown in Appendix D Figure 
D.1. 
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Figure 4.1. Identification of vGAT-IR cartridges and vGAT+ cartridge boutons. Projection image (5 z-planes 
taken 0.25 μm apart) of a human PFC tissue section immunolabeled for vGAT and GAD67. Single channel images of 
(A) GAD67, (B) vGAT, and (C) lipofuscin autofluorescence. (D) Merged image of A, B, and C. (E) Image from C 
overlaid with its corresponding object mask. (F-H) Image from B overlaid with its corresponding object masks (F), 
manually traced cartridge mask (G), and object masks from F that overlapped the cartridge mask from G (H). The 
cartridge mask was used to assess the density of cartridges between diagnostic groups, whereas the vGAT masks that 
overlapped the cartridge mask were used to assess relative fluorescence intensity levels in cartridge boutons. The 
asterisks designate an unlabeled soma. Bar = 10 μm. 
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4.2.3 Statistics 
Data are presented as mean cartridge density (± SD), mean bouton density (± SD), and mean sum 
fluorescence intensity (± SD). For measurements assessing cartridge density the cartridge masks 
were used (Figure 4.1G) and for measurements of vGAT+ cartridge bouton fluorescence 
intensity the vGAT object masks that overlapped a cartridge mask were used (Figure 4.1H). 
Because PV-IR cartridge boutons are GAD67+ (Fish et al., 2011; Glausier et al., 2014), vGAT 
object masks that overlapped a cartridge mask and a GAD65 object mask were excluded from 
analyses assessing GAD67 fluorescence intensity in vGAT+ cartridge boutons. 
 Two ANCOVA models were used to analyze cartridge number, bouton density, and 
bouton fluorescence intensity level data. Because subjects were selected and processed as pairs, 
the first paired ANCOVA model included cartridge density, bouton density, bouton vGAT levels, 
or bouton GAD67 levels as the dependent variable, diagnostic group as the main effect, subject 
pair as a blocking factor, and tissue storage time as a covariate. Subject pairing is an attempt to 
balance diagnostic groups for sex, age, and PMI, and to account for the parallel processing of 
tissue samples, and thus is not a true statistical paired design. Consequently, a second unpaired 
ANCOVA model was performed that included age, PMI, and tissue storage time as covariates. 
All statistical tests were conducted with α-level= 0.05. 
 We also assessed the potential influence of other factors that are frequently comorbid with 
the diagnosis of schizophrenia using ANCOVA models. For these analyses, we compared 
subjects with schizophrenia using each variable (sex; diagnosis of schizoaffective disorder; use of 
nicotine ATOD, antipsychotics ATOD, antidepressants ATOD, or benzodiazepines and/or sodium 
valproate ATOD) as the main effect and sex, age, tissue storage time, and PMI as covariates. A 
Bonferroni-adjusted α-level of 0.05/6 = 0.008 was used to assess significance. 
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 Reported ANCOVA statistics include only those covariates that were statistically 
significant. As a result, the reported degrees of freedom vary across analyses. 
4.3 RESULTS 
4.3.1 Cartridge density and vGAT+ boutons per cartridge are unchanged in schizophrenia 
The density of cartridges was not statistically different between diagnostic groups (paired F1, 19 = 
2.73, p = 0.115; unpaired F1, 38 = 2.72, p = 0.107); however, cartridge density was non-
significantly 12% greater in schizophrenia (1.01 ± 0.23 cartridges/counting frame) than 
comparison (0.90 ± 0.22 cartridges/counting frame) subjects (Figure 4.2A). Similarly, the number 
of vGAT+ boutons per cartridge did not differ (paired F1, 19 = 3.96, p = 0.061; unpaired F1, 38 = 
2.54, p = 0.119) between diagnostic groups, but were non-significantly 6% increased in the illness 
(schizophrenia: 16.45 ± 1.71 boutons/cartridge; comparison: 15.50 ± 2.04 boutons/cartridge; 
Figure 4.2B). 
4.3.2 Cartridge bouton GAD67 protein levels are unchanged in schizophrenia 
GAD67 protein levels in vGAT+ cartridge boutons were not statistically different between 
diagnostic groups (paired F1, 19 = 2.35, p = 0.142; unpaired F1, 38 = 2.46, p = 0.125), but were non-
significantly 12% lower in schizophrenia (638 ± 163 a.u.) than comparison (725 ± 186 a.u.) 
subjects (Figure 4.2C). Also, vGAT protein levels in vGAT+ cartridge boutons were unaltered 
(paired F1, 19 = 0.18, p = 0.676; unpaired F1, 38 = 0.15, p = 0.699) between diagnostic groups 
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(schizophrenia: 1498 ± 313 a.u.; comparison: 1463 ± 242 a.u.; Figure 4.2D). Because GAD67 
levels were only trending lower in chandelier cell boutons, these findings suggest that significant 
reductions in GAD67 protein levels may only affect GAD65+/GAD67+ boutons (e.g. PV basket 
cell boutons). Other subtypes of GABA neurons in primate PFC give rise to GAD67+ boutons 
(Rocco et al., 2015); therefore, we assessed the density and GAD67 protein levels in 
vGAT+/GAD65+/GAD67+ and vGAT+/GAD67+ boutons. 
 
 
 
 67 
 
 
Figure 4.2. Cartridge density, vGAT+ boutons per cartridge, and cartridge bouton GAD67 and vGAT protein 
levels between diagnostic groups. Mean cartridge density (A), vGAT+ boutons per cartridge (B), GAD67 protein 
levels in vGAT+ cartridge boutons (C), and vGAT protein levels in vGAT+ cartridge boutons (D) across layers 2-6. 
Each data point represents a schizophrenia (sz) and matched comparison (cntl) subject pair. Points below the unity 
line reflect pairs in which the measure is lower for the schizophrenia subject. 
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4.3.3 vGAT+/GAD65+/GAD67+ bouton density is lower in schizophrenia 
vGAT+/GAD65+/GAD67+ bouton density was 11% lower (paired F1, 19 = 5.80; unpaired p = 
0.026; F1, 38 = 6.62, p = 0.014) in schizophrenia (0.0097 ± 0.0017 boutons/µm
3
) relative to 
comparison (0.0109 ± 0.0014 boutons/µm
3
) subjects (Figure 4.3A). An analysis of all vGAT+ 
boutons that contained GAD65 immunoreactivity regardless of the presence of GAD67 
immunoreactivity (vGAT+/GAD65-IR boutons) found that the density of these boutons did not 
differ (paired F1, 19 = 0.03, p = 0.856; unpaired F1, 37 = 0.004, p = 0.948;) between diagnostic 
groups (schizophrenia: 0.0168 ± 0.0014 boutons/µm
3
; comparison: 0.0168 ± 0.0020 boutons/µm
3
; 
Figure 4.3B), which is similar to previous reports of no change in the density of GAD65-IR 
puncta in the PFC (Benes et al., 2000). These findings suggest that a proportion of 
vGAT+/GAD65+/GAD67+ boutons lack detectable GAD67 protein levels in schizophrenia. 
4.3.4 vGAT+/GAD65+/GAD67+ bouton GAD67 protein levels are lower in schizophrenia 
GAD67 protein levels were 17% lower (paired F1, 19 = 12.91, p = 0.002; unpaired F1, 38 = 12.55, p 
= 0.001;) in vGAT+/GAD65+/GAD67+ boutons in schizophrenia (927 ± 139 a.u.) relative to 
comparison (1115 ± 193 a.u.) subjects (Figure 4.3C). By contrast, vGAT protein levels in these 
boutons did not differ (paired F1, 19 = 0.13, p = 0.722; unpaired F1, 38 = 0.14, p = 0.713) between 
diagnostic groups (schizophrenia: 915 ± 140 a.u.; comparison: 931 ± 133 a.u.; Figure 4.3D).  
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Figure 4.3. vGAT+/GAD65+/GAD67+ bouton density, and GAD67 and vGAT protein levels between 
diagnostic groups. Mean vGAT+/GAD65+/GAD67+ bouton density (A), vGAT+/GAD65-IR bouton density (B), 
and GAD67 protein levels (C), and vGAT protein levels (D) in vGAT+/GAD65+/GAD67+ boutons in total gray 
matter. 
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4.3.5 vGAT+/GAD67+ bouton density is lower in schizophrenia 
The density of vGAT+/GAD67+ boutons was 24% lower (paired F1, 19 = 14.83, p = 0.001; 
unpaired F1, 38 = 15.10, p < 0.0005) in schizophrenia (0.0051 ± 0.0014 boutons/µm
3
) than 
comparison (0.0067 ± 0.0012 boutons/µm
3
) subjects (Figure 4.4A). This deficit was associated 
with a 26% increase (paired F1, 19 = 10.82, p = 0.004; unpaired F1, 38 = 7.57, p = 0.009) in the 
density of vGAT+ boutons without detectable GAD65 and/or GAD67 immunoreactivity 
(vGAT+/GAD- boutons) in the illness (schizophrenia: 0.0112 ± 0.0028 boutons/µm
3
; comparison 
0.0089 ± 0.0026 boutons/µm
3
; Figure 4.4B). Therefore, a proportion vGAT+/GAD67+ boutons 
lack detectable GAD67 protein levels in schizophrenia. 
4.3.6 vGAT+/GAD67+ bouton GAD67 protein levels are lower in schizophrenia 
GAD67 protein levels in vGAT+/GAD67+ boutons were 13% lower (paired F1, 18 = 14.74, p = 
0.001; unpaired F1, 36 = 5.61, p = 0.023) in schizophrenia (537 ± 94 a.u.) relative to comparison 
(617 ± 124 a.u.) subjects (Figure 4.4C). By contrast, vGAT protein levels in vGAT+/GAD67+ 
boutons did not differ (paired F1, 19 = 0.06, p = 0.817; unpaired F1, 37 = 0.13, p = 0.723) between 
diagnostic groups (schizophrenia: 617 ± 115 a.u.; comparison: 610 ± 95 a.u.; Figure 4.4D). 
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Figure 4.4. vGAT+/GAD67+ bouton density and GAD67 and vGAT protein levels between diagnostic groups. 
Mean vGAT+/GAD67+ bouton density (A), vGAT+ boutons without detectable GAD65 and/or GAD67 
immunoreactivity (vGAT+/GAD- boutons) density (B), and GAD67 protein levels (C) and GAD65 protein levels (D) 
in vGAT+/GAD67+ boutons in total gray matter. 
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4.3.7 Lower vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ bouton density and GAD67 
protein level measures are not attributable to comorbid factors 
In schizophrenia subjects, the density of vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ 
boutons, and GAD67 protein levels in vGAT+/GAD67+ boutons did not differ as a function of 
sex, diagnosis of schizoaffective disorder, or use of nicotine ATOD, benzodiazepine and/or 
sodium valproate ATOD, antidepressant ATOD, or antipsychotic ATOD (Appendix D Figures 
D.2 and D.3). By contrast, schizophrenia subjects on antidepressants ATOD had 16% lower levels 
of GAD67 in vGAT+/GAD65+/GAD67+ boutons (unpaired F1, 18 = 9.20, p = 0.007; Appendix D 
Figure D.3). To confirm that there was a disease effect on these measures, we reassessed each 
measure using the two analyses of covariance models described in 4.2.3 with antidepressants 
ATOD included as a covariate. GAD67 levels in vGAT+/GAD65+/GAD67+ boutons were still 
significantly lower in schizophrenia relative to comparison subjects for the paired analysis (paired 
F1, 19 = 12.91, p = 0.002; unpaired F1, 37 = 0.11, p = 0.748.) when antidepressant ATOD was 
included as a covariate. 
4.4 DISCUSSION 
About half of all PV neurons in the PFC of schizophrenia subjects lack detectable GAD67 mRNA 
expression (Hashimoto et al., 2003). Pre- and postsynaptic alterations at the site of PV chandelier 
cell inputs (Volk et al., 2002; Woo et al., 1998) are thought to compensate for reduced GABA 
signaling from these cells (Lewis, 2011), which led us to hypothesize that GAD67 protein levels 
are significantly reduced in boutons from chandelier cells. We found that the density of 
 73 
cartridges, which are distinctive structures formed by the convergence of multiple chandelier cell 
boutons at the AIS (Lewis and Lund, 1990), and boutons per cartridge were not significantly 
different between diagnostic groups but were trending higher in schizophrenia, and that GAD67 
protein levels in chandelier cell boutons were not significantly different between diagnostic 
groups but were trending lower in schizophrenia. 
 Our finding of a trending increase in the density of cartridges and boutons per cartridge 
across PFC layers 2-6 is consistent with a significantly greater density of AISs IR for the α2 
subunit of the GABA A receptor in PFC layers 2-superficial 3 in schizophrenia (Volk et al., 
2002). Although we do not report on density differences in specific layers, the α2-IR AIS findings 
suggest that the difference in cartridge density would be greatest in the superficial layers. In 
monkey PFC layers 2-4, the number of chandelier cell boutons per AIS decreases between 3 
months and adulthood (Fish et al., 2013). As a result, there is a reduction in the densities of 
cartridges IR for PV and GAT1, and α2-IR AISs (Anderson et al., 1995; Cruz et al., 2003). 
Together, these findings suggest that higher vGAT-IR cartridge and GABA A α2-IR AIS 
densities are the result of fewer chandelier cell boutons being pruned over development (Hoftman 
et al., 2013; Hyde et al., 2011). 
 By contrast, our finding of a trending increase in the density of vGAT-IR cartridges is not 
consistent with a significantly lower density of GAT1-IR cartridges across PFC layers 2-6 in 
schizophrenia (Woo et al., 1998). In the same study the overall density of GAT1-IR boutons was 
unchanged in the illness, suggesting that undetectable GAT1 immunoreactivity is specific to 
chandelier cells. Consistent with this idea, GAT1 mRNA expression is unchanged at the tissue 
level in schizophrenia (Hoftman et al., 2013), but is lower in PV neurons (Bitanihirwe and Woo, 
2014). Together with our results, these findings suggest that the lower density of GAT1-IR 
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cartridges in schizophrenia reflects a marked reduction in GAT1 protein levels in chandelier cell 
boutons. Pharmacological blockade of GAT1 increases the latency of postsynaptic responses 
upon GABA release at rat hippocampal synapses (Overstreet and Westbrook, 2003). Considering 
that GAD67 protein levels are only trending lower, vGAT protein levels are unaltered, and GAT1 
levels are significantly reduced at some chandelier cell inputs, similar effects may occur at 
chandelier cell synapses in the illness. Therefore, rather than compensating for lower GABA 
production from chandelier cells in schizophrenia, reductions in GAT1 may enhance their 
signaling effects. 
 The postsynaptic responses from chandelier cells are dynamic and highly responsive to 
network activity. By exclusively targeting the AIS, the site of action potential generation (Kole et 
al., 2008; Meeks and Mennerick, 2007; Palmer and Stuart, 2006), chandelier cells are thought to 
strongly regulate the output of pyramidal cells. While the synaptic effects of chandelier cells 
appear to be mainly inhibitory under physiological conditions (Woodruff et al., 2011), multiple 
studies have reported that they can also depolarize cortical and hippocampal pyramidal cells 
(Molnar et al., 2008; Sauer et al., 2012; Szabadics et al., 2006; Woodruff et al., 2011). These 
different effects are partially due to activity-dependent network fluctuations. For example, the 
effects from chandelier cell inputs are hyperpolarizing when the state of the network is highly 
active and depolarizing when the network is relatively quiescent (Woodruff et al., 2011). Reduced 
activity within the PFC of schizophrenia (Minzenberg et al., 2009) may favor more depolarizing 
responses from chandelier cells (Lewis, 2011). 
 These findings also suggest that reductions in GAD67 levels in schizophrenia affect PV 
basket cells to a greater degree than PV chandelier cells, which may result from a greater 
magnitude reduction in GAD67 mRNA expression in basket cells or a greater proportion of 
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basket cells being affected. In mouse somatosensory cortex, chandelier cells receive a greater 
percentage of excitatory afferent inputs from near layers 2-3 compared to basket cells, which 
receive most of their inputs from around layer 4 (Xu and Callaway, 2009). This is consistent with 
findings in mice suggesting that chandelier cells are enriched in layer 2 compared to deeper layers 
(Taniguchi et al., 2013). Therefore, GAD67 levels may be lower in PV basket cells because they 
receive a greater number of inputs from the middle PFC layers, which may have the greatest 
deficits in excitatory signaling in schizophrenia (Glausier and Lewis, 2013). 
 Since GAD67 protein levels are lower to a greater degree in PV basket cell boutons 
compared to chandelier cell boutons, and PV basket and chandelier cells give rise to 
GAD65+/GAD67+ and GAD67+ boutons, respectively (Fish et al., 2011; Glausier et al., 2014), 
we assessed if GAD67 levels were significantly lower in only GAD65+/GAD67+ boutons. We 
found that 11% of vGAT+/GAD65+/GAD67+ boutons lacked detectable GAD67 protein levels in 
schizophrenia, and that GAD67 protein levels were overall 17% lower in 
vGAT+/GAD65+/GAD67+ boutons. Similarly, GAD67 protein levels were undetectable in 24% 
of vGAT+/GAD67+ boutons, and GAD67 levels were overall 13% lower in these boutons. 
 Lower bouton GAD67 levels appear to be a consequence of schizophrenia pathology, and 
not of comorbid factors commonly associated with the illness. However, GAD67 levels in 
vGAT+/GAD65+/GAD67+ boutons were lower to a greater degree in subjects with schizophrenia 
taking antidepressants ATOD. Antidepressant use alone is unlikely to account for these affects 
since taking antidepressants was previously shown to not account for lower GAD67 mRNA and 
total protein expression in the PFC of schizophrenia subjects (Curley et al., 2011; Guidotti et al., 
2000). In this cohort, all schizophrenia subjects on antidepressants were also taking antipsychotics 
ATOD. Interestingly, chronic co-administration of fluvoxamine and haloperidol was shown to 
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reduce GAD67 protein levels in rat frontal cortex (Chertkow et al., 2006). By contrast, 
haloperidol alone resulted in a significant increase in both GAD67 mRNA and protein levels. Co-
administration of antidepressants and antipsychotics can improve negative symptoms (Silver, 
2003; Silver et al., 2000; Silver and Nassar, 1992), suggesting that the reduction of GAD67 within 
boutons might be beneficial in some subjects with schizophrenia. Future studies designed to 
directly assess the molecular and behavioral outcome of concomitantly taking these medications 
will be important for developing future pharmacotherapy strategies. 
 In concert, these findings suggest that lower GAD67 protein levels similarly affect 
neurons giving rise to GAD65+/GAD67+ and GAD67+ boutons in schizophrenia. However, it is 
unknown if significant reductions in GAD67 protein levels only affect GAD65+/GAD67+ 
boutons from PV basket cells. Moreover, non-statistically significant but trending reductions in 
GAD67 protein levels are unique to chandelier cells, and therefore it is unknown what GABA 
neuron subtype(s) give rise to GAD67+ boutons with significant reductions in GAD67 protein 
levels. A vast majority of GABA neurons in primate PFC can be grouped into non-overlapping 
subtypes by expressing PV, CB, or CR (Conde et al., 1994; del Rio and DeFelipe, 1996; Gabbott 
and Bacon, 1996). Both CB and CR neurons give rise to GAD65+/GAD67+ and GAD67+ 
boutons (Rocco et al., 2015), suggesting that they may be affected by significant reductions in 
GAD67 protein levels in schizophrenia; however, CB and CR neurons are thought to be 
differentially affected in the illness. For example, > 50% of CB neurons express SST (~85% of 
SST neurons contain CB) (Gonchar and Burkhalter, 1997; Kubota et al., 1994; Rogers, 1992). In 
schizophrenia, both the density of SST mRNA-positive neurons and levels of SST mRNA per 
neuron are lower in the PFC (Morris et al., 2008). Lower SST mRNA levels are correlated with 
lower GAD67 mRNA levels at both the tissue and cellular levels (Hashimoto et al., 2008; Morris 
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et al., 2008), suggesting that at least some boutons from CB neurons have significantly reduced 
GAD67 protein levels. By contrast, CR mRNA levels are unaltered and do not correlate with 
lower GAD67 mRNA levels in schizophrenia (Hashimoto et al., 2008), which is interpreted as CR 
neurons are unaffected (Hashimoto et al., 2008; Hashimoto et al., 2008; Hashimoto et al., 2003; 
Lewis et al., 2005; Volk et al., 2012). Importantly, CB and CR neurons play unique functional 
roles in the neuronal network and identifying if lower bouton GAD67 levels differentially affect 
these subtypes will be important for understanding the pathophysiological changes in 
schizophrenia. 
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5.0  GAD67 PROTEIN LEVELS ARE LOWER IN AXONAL BOUTONS FROM 
CALBINDIN AND CALRETININ NEURONS IN SCHIZOPHRENIA 
5.1 INTRODUCTION 
GAD67 protein levels are undetectable in 16% of axonal boutons in the PFC of schizophrenia 
subjects (3.0), which presumably arise from the ~30% of neurons that lack detectable GAD67 
mRNA expression (Akbarian et al., 1995; Volk et al., 2000). Marked reductions in GAD67 
expression affects neurons that give rise to GAD65+/GAD67+ and GAD67+ boutons. 
Specifically, 11% of GAD65+/GAD67+ boutons and 24% of GAD67+ boutons lack detectable 
GAD67 protein levels (4.0). ~50% of all PV neurons in the PFC of schizophrenia subjects lack 
detectable GAD67 mRNA expression (Hashimoto et al., 2003). All boutons from PV basket cells 
are GAD65+/GAD67+ (Fish et al., 2011; Glausier et al., 2014), and it was found that in PFC 
layers 3-4 of schizophrenia subjects GAD67 levels were ~50% lower in PV basket cell boutons, 
which were defined as the colocalization of PV-IR and GAD65-IR puncta with or without 
detectable GAD67 immunoreactivity (Curley et al., 2011). Along with the mRNA findings, these 
findings suggest that at least some PV basket cell boutons may lack detectable GAD67 protein 
levels. By contrast, PV chandelier cells give rise to GAD67+ boutons (Fish et al., 2011; Glausier 
et al., 2014), and in schizophrenia GAD67 protein levels are non-statistically significant 12% 
lower in boutons from chandelier cells (4.0). Therefore, it is unknown what subtypes of GABA 
 79 
neurons give rise to GAD67+ boutons with markedly reduced GAD67 protein levels, and if 
GAD65+/GAD67+ boutons from neuronal subtypes other than PV basket cells have marked 
reductions in GAD67 levels. 
Neurons that express PV, CB, and CR constitute ~25%, ~20%, and ~45%, respectively, of 
all GABA neurons in primate PFC (Conde et al., 1994; del Rio and DeFelipe, 1996; Gabbott and 
Bacon, 1996). At the transcript level, the majority of CB and CR neurons express mRNA for both 
GAD65 and GAD67 but a proportion of these neurons expresses mRNA for only GAD67 (Rocco 
et al., 2015). The finding that CB and CR neurons give rise to GAD67+ and GAD65+/GAD67+ 
boutons suggests that GAD67+ boutons arise from CB and CR neurons expressing only GAD67 
mRNA and GAD65+/GAD67+ boutons are from those neurons that express mRNAs for both 
GADs. Similarly, neurons that express SST, which includes > 50% of CB neurons (~85% of SST 
neurons contain CB) (Gonchar and Burkhalter, 1997; Kubota et al., 1994; Rogers, 1992), give rise 
to GAD67+ and GAD65+/GAD67+ boutons. 
GAD67 expression has not been assessed in CB and CR neurons in schizophrenia; 
however, correlative findings suggest that GAD67 levels are lower in CB, but not CR, neurons. 
For example, deficits in SST mRNA expression are widely reported in the PFC of schizophrenia 
subjects (Fung et al., 2010; Gabriel et al., 1996; Hashimoto et al., 2008; Hashimoto et al., 2008; 
Mellios et al., 2009; Morris et al., 2008). The density of SST mRNA-positive neurons and levels 
of SST mRNA per neuron are lower (Morris et al., 2008), and lower SST mRNA expression 
correlates with lower GAD67 mRNA expression at both the tissue and cellular levels (Hashimoto 
et al., 2008; Morris et al., 2008). By contrast, CR mRNA and total protein expression, as well as 
the density of CR-IR boutons are unaltered (Fung et al., 2010; Hashimoto et al., 2008; Hashimoto 
et al., 2003; Woo et al., 1998). CR mRNA levels do not correlate with lower GAD67 mRNA 
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levels in the illness (Hashimoto et al., 2008), suggesting that CR neurons are relatively unaltered. 
 Considering that PV neurons constitute ~25% of all GABA neurons and only half of all 
PV neurons have a marked deficit in GAD67 mRNA expression, they only account for ~12% out 
of the ~30% of GABA neurons that lack detectable GAD67 levels. Therefore, the remaining 
GABA neurons with markedly lower GAD67 expression may be comprised of SST neurons. 
Since CB/SST neurons give rise to GAD67+ and GAD65+/GAD67+ boutons, we hypothesize 
that in the PFC of schizophrenia subjects GAD67 protein levels are markedly lower in GAD67+ 
and GAD65+/GAD67+ boutons from CB neurons. By contrast, GAD67 levels in boutons arising 
from CR neurons are unaltered. 
5.2 MATERIALS AND METHODS 
5.2.1 Experimental procedures 
Specific procedures for tissue procurement, subject pairing, immunohistochemistry, and data 
collection and segmentation are described in 2.0. Briefly, PFC tissue sections from 20 pairs of 
schizophrenia and matched comparison subjects (Table 2.1) were immunolabeled for vGAT, 
GAD65, GAD67, and CB or CR (Table 2.2). Quantitative confocal microscopy techniques were 
used to assess bouton density and relative fluorescence intensity levels within total gray matter. 
5.2.2 Definitions of CB and CR boutons 
vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ boutons were classified as containing 
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immunoreactivity for CB (CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+) or CR 
(CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+) using a multistep process. 
Initially, vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ boutons were defined as described in 
2.6.2. Mask operations were then used to identify vGAT object masks from these distinct bouton 
subpopulations and CB or CR object masks that overlapped each other’s centers. Next, for each 
site the mean fluorescence intensity of CB or CR for all CB+/vGAT+/GAD+ and 
CR+/vGAT+/GAD+ boutons classified using mask operations criteria were used as seeds in a K-
means cluster analysis to classify the remaining vGAT+/GAD+ boutons as CB+ or CR+. Figure 
5.1 shows examples of CB+ boutons and Figure 5.2 shows examples of CR+ boutons classified 
as vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+. 
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Figure 5.1. Examples of CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ boutons. Projection image 
(3 z-planes taken 0.25 μm apart) of a human PFC tissue section immunolabeled for CB, vGAT, GAD65, and GAD67. 
Single channel images of (A) GAD65, (B) GAD67, (C) CB, (D) vGAT, and (E) lipofuscin autofluorescence. (F) 
Merged image of A, B, and C. (G) Merged image of A, B, D. (H) Object masks corresponding to A, B, and D. (I) 
Object masks corresponding to A, B, and C. Arrows indicate CB+/vGAT+/GAD67+ (arrowheads) and 
CB+/vGAT+/GAD65+/GAD67+ (arrow) boutons. Bar = 5 μm. 
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Figure 5.2. Examples of CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ boutons. Projection image 
(3 z-planes taken 0.25 μm apart) of a human PFC tissue section immunolabeled for CR, vGAT, GAD65, and GAD67. 
Single channel images of (A) GAD65, (B) GAD67, (C) CR, (D) vGAT, and (E) lipofuscin autofluorescence. (F) 
Merged image of A, B, and C. (G) Merged image of A, B, D. (H) Object masks corresponding to A, B, and D. (I) 
Object masks corresponding to A, B, and C. Arrows indicate CR+/vGAT+/GAD67+ (arrowheads) and 
CR+/vGAT+/GAD65+/GAD67+ (arrows) boutons. Bar = 5 μm. 
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5.2.3 Statistics 
Data are presented as mean bouton density (± SD), and mean sum fluorescence intensity (± SD). 
Two ANCOVA models were used to analyze bouton density and bouton protein level data. 
Because subjects were selected and processed as pairs, the first paired ANCOVA model included 
bouton density, bouton GAD67 levels, bouton CB levels, bouton CR levels, and bouton vGAT 
levels as the dependent variable, diagnostic group as the main effect, subject pair as a blocking 
factor, and tissue storage time as a covariate. Subject pairing is an attempt to balance diagnostic 
groups for sex, age, and PMI, and to account for the parallel processing of tissue samples, and 
thus is not a true statistical paired design. Consequently, a second unpaired ANCOVA model was 
performed that included age, PMI, and tissue storage time as covariates. All statistical tests were 
conducted with α-level= 0.05. 
We also assessed the potential influence of other factors that are frequently comorbid with 
the diagnosis of schizophrenia using ANCOVA models. For these analyses, we compared 
subjects with schizophrenia using each variable (sex; diagnosis of schizoaffective disorder; use of 
nicotine ATOD, antipsychotics ATOD, antidepressants ATOD, or benzodiazepines and/or sodium 
valproate ATOD) as the main effect and age, PMI, tissue storage time, and sex as covariates. A 
Bonferroni-adjusted α-level of 0.05/6 = 0.008 was used to assess significance. 
Reported ANCOVA statistics include only those covariates that were statistically 
significant. As a result, the reported degrees of freedom vary across analyses. 
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5.3 RESULTS 
5.3.1 CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton density is 
unaltered in schizophrenia 
The density of CB+/vGAT+/GAD67+ boutons did not differ (paired F1, 19 = 3.50, p = 0.077; 
unpaired F1, 38 = 2.37, p = 0.132) between schizophrenia (0.00080 ± 0.00029 boutons/µm
3
) and 
comparison (0.00092 ± 0.00024 boutons/µm
3
) subjects (Figure 5.3A). Similarly, the density of 
CB+/vGAT+/GAD65+/GAD67+ boutons did not differ (paired F1, 19 = 0.18, p = 0.678; unpaired 
F1, 38 = 0.13, p = 0.719) between diagnostic groups (schizophrenia: 0.00071 ± 0.00031 
boutons/µm
3
; comparison: 0.00074 ± 0.00025 boutons/µm
3
; Figure 5.3B). Thus, GAD67 protein 
levels were detectable in the vast majority of CB+/vGAT+/GAD67+ and 
CB+/vGAT+/GAD65+/GAD67+ boutons in schizophrenia. 
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Figure 5.3. CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton density between diagnostic 
groups. Mean density of CB+/vGAT+/GAD67+ boutons (A) and CB+/vGAT+/GAD65+/GAD67+ boutons (B) in 
total gray matter. Each data point represents a schizophrenia (sz) and matched comparison (cntl) subject pair. Points 
below the unity line reflect pairs in which the measure is lower for the schizophrenia subject. 
 
 
 
 
5.3.2 CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton GAD67 protein 
levels are lower in schizophrenia 
GAD67 protein levels were 15% lower (paired F1, 18 = 6.70, p = 0.019; unpaired F1, 37 = 5.66, p = 
0.023) in CB+/vGAT+/GAD67+ boutons in schizophrenia (843 ± 155 a.u.) relative to comparison 
(994 ± 239 a.u.) subjects (Figure 5.4A1). Similarly, GAD67 levels in 
CB+/vGAT+/GAD65+/GAD67+ boutons were 17% lower (paired F1, 19 = 11.21, p = 0.003; 
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unpaired F1, 37 = 11.39, p = 0.002) in the illness (schizophrenia: 1337 ± 213 a.u.; comparison: 
1605 ± 294 a.u.; Figure 5.4B1). 
5.3.3 CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton CB protein levels 
are lower in schizophrenia 
CB protein levels in CB+/vGAT+/GAD67+ boutons were 14% lower (paired F1, 19 = 4.88, p = 
0.04; unpaired F1, 37 = 5.02, p = 0.031) in schizophrenia (458 ± 102 a.u.) relative to comparison 
(535 ± 125 a.u.) subjects (Figure 5.4A2). Similarly, CB levels in 
CB+/vGAT+/GAD65+/GAD67+ boutons were 13% lower (paired F1, 19 = 5.72, p = 0.027; 
unpaired F1, 37 = 5.65, p = 0.023) in the illness (schizophrenia: 427 ± 75 a.u.; comparison: 493 ± 
103 a.u.; Figure 5.4B2). 
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Figure 5.4. CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton GAD67 and CB protein levels 
between diagnostic groups. Mean GAD67 protein levels (A1 and B1) and CB protein levels (A2 and B2) in 
CB+/vGAT+/GAD67+ (A) and CB+/vGAT+/GAD65+/GAD67+ (B) boutons in total gray matter. 
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5.3.4 CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton vGAT protein 
levels are unaltered in schizophrenia 
Levels of vGAT protein did not differ within CB+/vGAT+/GAD67+ boutons (paired F1, 19 = 0.58, 
p = 0.458; unpaired F1, 38 = 0.53, p = 0.47) and CB+/vGAT+/GAD65+/GAD67+ boutons (paired 
F1, 19 = 0.02, p = 0.886; unpaired F1, 38 = 0.02, p = 0.884) between schizophrenia 
(CB+/vGAT+/GAD67+ boutons: 815 ± 175 a.u.; CB+/vGAT+/GAD65+/GAD67+ boutons: 1081 
± 206 a.u.) and comparison (CB+/vGAT+/GAD67+ boutons: 778 ± 143 a.u.; 
CB+/vGAT+/GAD65+/GAD67+ boutons: 1072 ± 167 a.u.) subjects (Appendix E Figures E.1). 
5.3.5 Differences in CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton 
GAD67 and CB protein levels in schizophrenia are not attributable to comorbid factors 
In schizophrenia subjects, GAD67 and CB protein levels in CB+/vGAT+/GAD67+ and 
CB+/vGAT+/GAD65+/GAD67+ boutons did not differ as a function of sex, nicotine use ATOD, 
benzodiazepine and/or sodium valproate ATOD, antidepressant ATOD, antipsychotic ATOD, or 
diagnosis of schizoaffective disorder (Appendix E Figures E.2 and E.3). 
5.3.6 CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton density is lower 
in schizophrenia 
The density of CR+/vGAT+/GAD67+ boutons was 22% lower (paired F1, 19 = 7.78, p = 0.012; 
unpaired F1, 38 = 7.63, p = 0.009) in schizophrenia (0.00075 ± 0.00024 boutons/µm
3
) than 
comparison (0.00096 ± 0.00024 boutons/µm
3
) subjects (Figure 5.5A). These findings suggest that 
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a subset of CR+/vGAT+/GAD67+ boutons lack detectable GAD67 protein levels. In support of 
our interpretation, the density of CR+/vGAT+ boutons that lacked detectable GAD65 and/or 
GAD67 immunoreactivity was 21% greater (paired F1, 19 = 5.31, p = 0.033; unpaired F1, 38 = 3.80, 
p = 0.059) in the illness (schizophrenia: 0.00141 ± 0.00035 boutons/µm
3
; comparison: 0.00117 ± 
0.00041 boutons/µm
3
; Appendix E Figures E.4).  
Similarly, CR+/vGAT+/GAD65+/GAD67+ bouton density was 19% lower (paired F1, 19 = 
5.02, p = 0.037; unpaired F1, 38 = 4.03, p = 0.052) in schizophrenia (0.00096 ± 0.00029 
boutons/µm
3
) than comparison (0.001184 ± 0.00041 boutons/µm
3
) subjects (Figure 5.5B), 
suggesting that GAD67 protein levels are undetectable in a subset of these boutons. By contrast, 
the density of CR+/vGAT+/GAD65+ boutons was 23% greater (paired F1, 19 = 5.72, p = 0.027; 
unpaired F1, 37 = 4.79, p = 0.035) in the illness (schizophrenia: 0.00054 ± 0.00016 boutons/µm
3
; 
comparison: 0.00044 ± 0.00017 boutons/µm
3
; Appendix E Figures E.4). An analysis of all 
CR+/vGAT+ boutons containing GAD65 immunoreactivity (i.e. CR+/vGAT+/GAD65+ and 
CR+/vGAT+/GAD65+/GAD67+ boutons) found that their density did not differ (paired F1, 19 = 
1.31, p = 0.266; unpaired F1, 37 = 0.82, p = 0.37) between diagnostic groups (schizophrenia: 
0.00149 ± 0.00027 boutons/µm
3
; comparison: 0.00162 ± 0.00053 boutons/µm
3
; Appendix E 
Figures E.4). These findings support the idea that a subset of CR+/vGAT+/GAD65+/GAD67+ 
boutons lack detectable GAD67 levels in schizophrenia. 
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Figure 5.5. CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton density between diagnostic 
groups. Mean density of CR+/vGAT+/GAD67+ boutons (A) and CR+/vGAT+/GAD65+/GAD67+ boutons (B) in 
total gray matter. 
 
 
 
 
5.3.7 CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton GAD67 protein 
levels are lower in schizophrenia 
GAD67 protein levels in CR+/vGAT+/GAD67+ boutons were 12% lower (paired F1, 19 = 5.95, p 
= 0.025; unpaired F1, 37 = 4.30, p = 0.045) in schizophrenia (306 ± 65 a.u.) relative to comparison 
(351 ± 75 a.u.) subjects (Figure 5.6A1). Similarly, GAD67 levels in 
CR+/vGAT+/GAD65+/GAD67+ boutons were 15% lower (paired F1, 19 = 9.49, p = 0.006; 
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unpaired F1, 37 = 7.39, p = 0.01) in the illness (schizophrenia: 491 ± 91 a.u.; comparison: 576 ± 
113 a.u.; Figure 5.6B1). 
5.3.8 CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton CR protein levels 
are unaltered in schizophrenia 
CR protein levels in CR+/vGAT+/GAD67+ boutons did not differ (paired F1, 19 = 0.39, p = 0.541, 
unpaired F1, 37 = 0.13, p = 0.723) between diagnostic groups (schizophrenia: 559 ± 130 a.u.; 
comparison: 578 ± 126 a.u.; Figure 5.6A2). Similarly, CR levels in 
CR+/vGAT+/GAD65+/GAD67+ boutons did not differ (paired F1, 18 = 3.48, p = 0.079, unpaired 
F1, 37 = 2.31, p = 0.137; Figure 5.6B2) between groups (schizophrenia: 664 ± 147 a.u.; 
comparison: 740 ± 165 a.u.). 
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Figure 5.6. CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton GAD67 and CR protein levels 
between diagnostic groups. Mean GAD67 protein levels (A1 and B1) and CR protein levels (A2 and B2) in 
CR+/vGAT+/GAD67+ (A) and CR+/vGAT+/GAD65+/GAD67+ (B) boutons in total gray matter. 
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5.3.9 CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton vGAT protein 
levels are unaltered in schizophrenia 
Levels of vGAT protein were not different in CR+/vGAT+/GAD67+ boutons (paired F1, 18 = 0.0, 
p = 0.99, unpaired F1, 37 = 0.02, p = 0.884) and CR+/vGAT+/GAD65+/GAD67+ boutons (paired 
F1, 18 = 0.28, p = 0.601; unpaired F1, 37 = 0.41, p = 0.524) between schizophrenia 
(CR+/vGAT+/GAD67+ boutons: 622 ± 123 a.u.; CR+/vGAT+/GAD65+/GAD67+ boutons: 935 
± 162 a.u.) and comparison (CR+/vGAT+/GAD67+ boutons: 632 ± 120 a.u.; 
CR+/vGAT+/GAD65+/GAD67+ boutons: 973 ± 176 a.u.) subjects (Appendix E Figures E.5). 
5.3.10 Differences in CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton 
density and GAD67 protein levels in schizophrenia are not attributable to comorbid factors 
In schizophrenia subjects, CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton 
density and GAD67 protein levels did not differ as a function of sex, nicotine use ATOD, 
benzodiazepine and/or sodium valproate ATOD, antidepressant ATOD, antipsychotic ATOD, or 
diagnosis of schizoaffective disorder (Appendix D Figures D.6 and E.7). 
5.4 DISCUSSION 
Convergent findings led us to hypothesize that GAD67 protein levels are undetectable in 
GAD67+ and GAD65+/GAD67+ boutons from CB neurons, but not CR neurons. Our findings 
rejected these hypotheses. Specifically, we found no statistical difference in the density of 
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CB+/vGAT+/GAD67+ or CB+/vGAT+/GAD65+/GAD67+ boutons between diagnostic groups, 
suggesting that GAD67 immunoreactivity was detectable in all GAD67-IR boutons from CB 
neurons. However, GAD67 levels were 15% lower in CB+/vGAT+/GAD67+ boutons and 17% 
lower in CB+/vGAT+/GAD65+/GAD67+ boutons in schizophrenia. By contrast, 22% and 19% 
of CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ boutons, respectively, lacked 
detectable GAD67 protein levels in the illness. Moreover, GAD67 levels were 12% lower in 
CR+/vGAT+/GAD67+ boutons and 15% lower in CR+/vGAT+/GAD65+/GAD67+ boutons. In 
concert, our findings suggest that a significantly greater proportion of CR boutons contribute to 
the 24% of GAD67+ boutons and the 11% of GAD65+/GAD67+ boutons with markedly reduced 
GAD67 protein levels, respectively (4.0), compared to CB boutons. Our findings also suggest that 
CR neurons have a greater magnitude reduction in GAD67 mRNA expression than CB neurons, 
which may be due to a greater number of CR neurons affected by reduced GAD67 mRNA 
expression, a greater percentage reduction in GAD67 expression in CR neurons, or both. 
CB is expressed in diverse subtypes of cortical GABAergic neurons and glutamatergic 
pyramidal cells (DeFelipe et al., 1989; Freund et al., 1990; Gonzalez-Albo et al., 2001; Hayes and 
Lewis, 1992; Hof and Morrison, 1991). Much of what is known about alterations in GABAergic 
CB neurons in schizophrenia comes from studying neurons that express SST, which is exclusively 
expressed by GABA neurons (Gonchar and Burkhalter, 1997; Gonchar and Burkhalter, 2003; 
Gonzalez-Albo et al., 2001; Kubota et al., 1994; Sugino et al., 2006). The detectability of SST 
immunoreactivity is rapidly degraded postmortem (Hayes et al., 1991) compared to other proteins 
including CB, which greatly confounds assessments of SST protein levels in human brain tissue. 
Our findings here report on measurements exclusively from GABAergic CB boutons because 
only those CB boutons that were IR for vGAT were included. 
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We found that CB protein levels were 14% and 13% lower in CB+/vGAT+/GAD67+ and 
CB+/vGAT+/GAD65+/GAD67+ boutons, respectively. Findings in mouse somatosensory cortex 
suggest that CB neurons receive the greatest strength of excitatory drive from pyramidal cells 
around layer 4 (Xu and Callaway, 2009). In schizophrenia, pyramidal cells in layers deep 3-4 
appear to have the greatest deficits in excitatory drive (reviewed in Glausier and Lewis, 2013). 
Considering that decreased network activity result in lower CB (Carder et al., 1996; Philpot et al., 
1997) and GAD67 (Lau and Murthy, 2012) protein expression, lower bouton CB and GAD67 
protein levels in schizophrenia may be a consequence of deficits in excitatory drive from 
pyramidal cells in PFC layers deep 3-4.  
GABAergic CB neurons constitute numerous morphologically diverse neuronal subtypes; 
however, their synaptic targets and function are generally similar. CB neurons mainly innervate 
dendritic spines and shafts of pyramidal cells (Melchitzky and Lewis, 2008) and to a lesser extent 
the dendrites of non-SST expressing GABA neurons (Pfeffer et al., 2013), whereby they regulate 
the integration of excitatory inputs within local cortical circuits (Lovett-Barron et al., 2012) and 
from thalamic afferents (Xu et al., 2013), and provide feedback inhibition in and between cortical 
layers (Wang et al., 2004). Recent in vitro findings suggest that SST neurons in layer 2 of mouse 
somatosensory cortex are spontaneously and tonically active and thereby provide a blanket of 
strong inhibition over the cortical network via activation of GABA B receptors (Urban-Ciecko et 
al., 2015). Suppressing the activity of these neurons using optogenetic techniques increases the 
overall excitability of local pyramidal cells. Several functional imaging studies have shown 
reduced activity of the PFC in schizophrenia subjects (Berman et al., 1986; Glahn et al., 2005; 
Minzenberg et al., 2009; Perlstein et al., 2003; Weinberger et al., 1988; Weinberger et al., 1986). 
Protein levels for GABA B receptor subunits are reduced in the PFC (Ishikawa et al., 2005) as 
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well as mRNA expression for α5-containing GABA A receptors (Beneyto et al., 2011), which are 
enriched at synapses from SST neurons (Ali and Thomson, 2008; Serwanski et al., 2006). 
Together with our finding of less GABA production, and presumably release, from CB neurons, 
these changes may be compensatory responses to less PFC activity in order to achieve greater 
excitability of pyramidal cells. 
Our findings of markedly reduced GAD67 protein levels in boutons from CR neurons in 
schizophrenia were not due to lack of detectable bouton CR immunoreactivity since CR protein 
levels were unchanged in these boutons. This finding is consistent with previous reports of no 
change in CR mRNA expression or total protein levels in the PFC of schizophrenia subjects 
(Fung et al., 2010; Hashimoto et al., 2008; Hashimoto et al., 2003). Unlike CB and GAD67 
protein expression, CR protein levels do not appear to be as responsive to changes in network 
activity (Carder et al., 1996; Philpot et al., 1997). These properties likely explain why CR mRNA 
expression did not correlate with lower levels of GAD67 mRNA expression in previous studies of 
schizophrenia (Hashimoto et al., 2008), which has been interpreted as CR neurons are unaffected 
in the illness.  
In contrast to pyramidal cells in PFC layers deep 3-4 in schizophrenia, pyramidal cells in 
other PFC layers show less robust alterations in markers of excitatory drive. This may be due to 
intrinsic deficits in pyramidal cells in layers deep 3-4 and/or deficits in cortico-cortical and 
thalamo-cortical inputs, which predominantly innervate these cortical layers (Barbas and Rempel-
Clower, 1997; Felleman and Van Essen, 1991; Giguere and Goldman-Rakic, 1988; Jones and 
Hendry, 1989). The majority of local excitatory afferents to CR neurons are from pyramidal cells 
in layers 2-3 (Xu and Callaway, 2009). However, our finding that GAD67 protein levels are 
markedly reduced in boutons from CR neurons suggests that excitatory drive from pyramidal cells 
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in the superficial layers is also reduced in schizophrenia subjects, which may be a consequence of 
reductions in the strength of excitatory drive from local axon collaterals of pyramidal cells in 
layers deep 3-4 (Melchitzky et al., 2001; Melchitzky et al., 1998). 
Alternatively, > 80% of CR neurons express VIP (Gabbott and Bacon, 1997), and 
microduplications in the VIP receptor gene, VIPR2, confers increased risk for schizophrenia 
(Levinson et al., 2011; Vacic et al., 2011; Yuan et al., 2014); however, the VIPR2 
microduplication was found to be only present in 0.35% out of > 8,000 schizophrenia subjects 
(Vacic et al., 2011). Pharmacological-induced overactivation of the VPAC2 receptor, which is 
encoded by VIPR2, in infant mice leads to lower PFC levels of postsynaptic density-95 (PSD-95) 
and synaptophysin protein, and sensorimotor gating abnormalities (Ago et al., 2015). 
Schizophrenia subjects are reported to have lower cortical protein levels for PSD-95 and 
synaptophysin (Glantz and Lewis, 1997; Kristiansen et al., 2006) and lower PSD-95 mRNA 
expression in the PFC (Ohnuma et al., 2000). Moreover, sensorimotor gating abnormalities are 
present in the illness (Braff et al., 1999; Swerdlow et al., 2006). Therefore, intrinsic alterations in 
the overexpression of the VIPR2 gene in some subjects with schizophrenia may lead to synaptic 
abnormalities in the PFC. Although it is unknown if any subjects in this cohort carried this 
microduplication, the low prevalence of this genomic alteration is unlikely to account for our 
findings. 
Similar to CB neurons, CR neurons constitute a morphologically diverse subtype of 
GABA neuron. CR neurons play a unique disinhibitory role by mainly contacting the dendrites of 
other GABA neurons and to a much lesser extent the dendrites and perisomatic region of 
pyramidal cells (Melchitzky et al., 2005; Melchitzky and Lewis, 2008). Studies in mouse suggest 
that CR/VIP neurons primarily innervate SST and to a lesser extent PV neurons, and that this 
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innervation pattern occurs across cortical and hippocampal regions (Donato et al., 2013; Fu et al., 
2014; Kawaguchi Y, 1996; Lee et al., 2013; Neske et al., 2015; Pfeffer et al., 2013; Rogers, 1992; 
Staiger et al., 2004; Tyan et al., 2014). By mainly contacting GABA neurons, CR/VIP neurons 
mediate selective amplification of local signal processing of pyramidal cells (Pi et al., 2013). A 
reduced capacity for GABA synthesis, and presumably signaling, from CR neurons would 
decrease the amount of disinhibition of pyramidal cells, which may contribute to lower PFC 
activity in schizophrenia. 
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6.0  GENERAL DISCUSSION 
6.1 SUMMARY OF FINDINGS 
Cognitive impairments are a core feature of schizophrenia and arise, in part, from alterations in 
glutamatergic and GABAergic signaling in the PFC. ~30% of GABA neurons have marked 
reductions in GAD67 mRNA expression, and the goal of this dissertation was to determine which 
GABA neuron subtypes are affected by this deficit. Development of a novel technique to identify 
lipofuscin (2.0) was required to ask the following specific questions about GABAergic signaling 
deficits in schizophrenia: 1) How well do bouton GAD67 protein levels reflect the prior findings 
of markedly lower GAD67 mRNA expression in only a subset of GABA neurons? (3.0); 2) Are 
GAD67 protein levels lower in chandelier cell boutons? (4.0); 3) Are GAD67 protein levels lower 
in boutons arising from CB, but not CR, neurons? (5.0). The following discussion reviews the 
findings of the experimental chapters, and presents a mechanistic hypothesis for the cause of 
lower GAD67 expression in the affected GABA neuron subtypes. Finally, the implication of this 
work for altered PFC activity in schizophrenia will be considered. 
6.1.1 Lower GAD67 protein levels in a subset of boutons in schizophrenia 
Reductions in GAD67 mRNA expression are widely reported in the PFC of schizophrenia 
subjects but only ~30% of GABA neurons in the PFC lack detectable levels of GAD67 mRNA, 
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whereas the other neurons contain GAD67 mRNA around normal levels (Akbarian et al., 1995; 
Volk et al., 2000). We found that the reported marked reduction in GAD67 mRNA levels reflect a 
marked reduction in GAD67 protein levels in only a subset of GABAergic boutons. Specifically, 
only 16% of vGAT+ boutons lacked detectable levels of GAD67 protein, and GAD67 levels were 
14% lower in boutons that contained GAD67 immunoreactivity (3.0); however, lower GAD67 
levels did not affect all boutons similarly. The range of GAD67 levels, including boutons with 
relatively high levels of GAD67, were similar between diagnostic groups, suggesting that only a 
subset of boutons has reduced GAD67 protein levels in schizophrenia, which presumably arise 
from the neurons with marked deficits in GAD67 mRNA expression. By contrast, the density of 
vGAT+ boutons was unaltered (3.0). Moreover, bouton vGAT protein levels were not different in 
all GABAergic boutons or in boutons from any of the GABA neuron subtypes assessed (4.0 and 
5.0), which corroborates previous vGAT mRNA findings in the illness (Fung et al., 2011; 
Hoftman et al., 2013), and suggests that the capacity to package GABA into synaptic vesicles is 
overall intact despite lower GABA production. 
6.1.2 GAD67 expression in GABA neuron subtypes in schizophrenia 
PV, CB, and CR neurons constitute ~25%, ~20%, and ~45% of all GABA neurons in primate 
neocortex (Conde et al., 1994; del Rio and DeFelipe, 1996; Gabbott and Bacon, 1996). Since 
about half of all PV neurons lack detectable GAD67 mRNA expression (Hashimoto et al., 2003), 
GAD67 protein levels are ~50% reduced in boutons from PV basket cells in PFC layers 3-4 
(Curley et al., 2011), and correlative evidence suggest that GAD67 expression is lower in PV 
chandelier and SST, but not CR neurons (Hashimoto et al., 2008; Morris et al., 2008), it was 
unknown if the ~30% of neurons with marked reductions in GAD67 mRNA expression were 
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comprised of only PV and SST neurons. Our findings that GAD67 protein levels were trending 
lower in chandelier cell boutons (4.0), significantly lower in boutons from CB and CR neurons 
(5.0) suggest that no single subtype is completely affected by lower GAD67 expression in 
schizophrenia, but rather a proportion of each subtype contributes to the pool of GABA neurons 
with marked reductions in GAD67 expression. 
6.2 LOWER BOUTON GAD67 PROTEIN LEVELS AS A CONSEQUENCE OF 
REDUCED ACTIVITY IN SCHIZOPHRENIA 
6.2.1 Local excitatory afferent inputs 
Studies in mouse somatosensory cortex suggest that PV and CB neurons receive the greatest 
strength of excitatory drive from pyramidal cells in layers deep 3-4, whereas CR neurons receive 
the greatest drive from pyramidal cells in layers 2-superficial 3 (Xu and Callaway, 2009). 
Although this connectivity pattern may be different in other cortical areas and in human PFC, our 
findings suggest that GAD67 expression may be reduced as a compensatory response to overall 
lower activity of the PFC and not necessarily predicted by the amount or strength of inputs from 
layers deep 3-4 pyramidal neurons; however, lower PFC activity may be a consequence of cell-
autonomous deficits in layers deep 3-4 pyramidal cells, a reduction in the strength of feedforward 
afferent inputs to these layers, or a combination of both possibilities (reviewed in Glausier and 
Lewis, 2013). About half of all local axon collaterals from layers deep 3-4 pyramidal cells and 
~90% of afferents from deep 3-4 pyramidal cells in proximal cortical areas innervate dendritic 
spines, including spines in the superficial layers (Melchitzky et al., 2001; Melchitzky et al., 1998). 
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Therefore, reductions in the activity of pyramidal cells in the superficial layers may be a 
consequence of reduced strength of excitatory drive from pyramidal cells in layers deep 3-4, and 
in turn, lead to overall reduced activity of the PFC and lower GAD67 expression in neurons that 
may not receive direct inputs from layers deep 3-4 pyramidal cells. 
6.2.2 Extrinsic excitatory afferent projections 
Dendritic spines of layers deep 3-4 pyramidal cells are the principal targets of the vast majority of 
thalamo-cortical (Giguere and Goldman-Rakic, 1988; Jones and Hendry, 1989) and cortico-
cortical projections (Medalla and Barbas, 2009; Melchitzky et al., 2001); however, afferent 
projections from distinct brain regions preferentially innervate distinct subtypes of GABA 
neurons. In rat, afferent projections from the mediodorsal thalamic nuclei to the PFC 
predominantly target PV neurons (Rotaru et al., 2005). In monkey PFC, CB neurons are the 
predominant GABAergic subtype that receives projections from the ACC (Medalla and Barbas, 
2009; Medalla and Barbas, 2010), presumably from layer 3 pyramidal cells (Barbas and Rempel-
Clower, 1997), whereas CR neurons are the predominant GABAergic subtype that receives layer 
3 projections from pyramidal cells in adjacent PFC areas (e.g. projections in area 46 to area 9) 
(Medalla and Barbas, 2009). This connectivity pattern suggests that deficits in excitatory drive 
from extrinsic brain regions may contribute to lower GAD67 expression in PV, CB, and CR 
neurons in the PFC of schizophrenia subjects.  
Indeed, deficits in total neuron number and volume of the mediodorsal thalamic nuclei, the 
number of putative thalamic projections to the PFC, and transcripts encoding glutamate receptor 
subunits in the thalamus are reduced in schizophrenia (Byne et al., 2001; Byne et al., 2002; 
Gilbert et al., 2001; Lewis et al., 2001; Pakkenberg, 1990; Popken et al., 2000; Sodhi et al., 2011; 
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Young et al., 2000); therefore, reduced excitatory drive from the thalamus may contribute to 
lower GAD67 levels in PV neurons (Figure 6.1). It is currently unknown if thalamic projections 
preferentially innervate PV basket or chandelier cells; however, considering that the highest 
density of chandelier cells is in layers 2 and 6 (Taniguchi et al., 2013), the highest density of all 
PV neurons is in layers deep 3-4 (Conde et al., 1994), and thalamic inputs predominantly 
innervate layers deep 3-4 (Giguere and Goldman-Rakic, 1988; Jones and Hendry, 1989), PV 
basket cells may receive a greater density of thalamic inputs compared to chandelier cells. 
Therefore, a greater magnitude reduction in GAD67 protein levels in boutons from PV basket 
cells than chandelier cells may be a consequence of deficits in the strength of thalamic afferents in 
combination with reduced drive from local pyramidal cells. 
 Similar to the PFC, morphological deficits in layer 3 pyramidal cells of the ACC are 
reported in schizophrenia (Broadbelt et al., 2002), and numerous functional imaging studies 
suggest that the activity of both of these brain regions is altered in schizophrenia patients during 
cognitive control tasks (Allen et al., 2007; Cho et al., 2006; Ikuta et al., 2012; Kerns et al., 2005; 
Minzenberg et al., 2010; Quintana et al., 2004; Schultz et al., 2012; Yucel et al., 2007). Therefore, 
lower excitatory drive from the ACC may contribute to lower GAD67 expression in CB neurons, 
and reduced excitatory drive from other nearby PFC areas may contribute to lower GAD67 
expression in CR neurons. 
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Figure 6.1. Schematic diagram of GAD67 expression alterations in GABA neuron subtypes of PFC area 9 in 
response to reduced local excitatory drive from layers deep 3-4 pyramidal cells and extrinsic brain regions. 
The asterisk indicates GAD67 protein level findings in boutons from PV basket cells (PVb) in PFC layers 3-4 of 
schizophrenia subjects (Curley et al., 2011). Bouton GAD67 expression levels from PV chandelier (PVch), CB, and 
CR neurons are reported in 4.0 and 5.0. The thicker lines from the pyramidal cell (PYR), thalamus, anterior cingulate 
cortex (ACC), and PFC area 46 depict greater strength of excitatory drive to PV, CB, and CR neurons. 
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6.2.3 Lower expression of several GABA-related markers 
Converging evidence suggests that reduced expression of various other activity-dependent 
GABA-related markers accompany lower GAD67 expression in schizophrenia. For example, 
monocular deprivation in monkeys result in lower PV and CB immunoreactivity (Carder et al., 
1996), and similar reductions in PV and CB protein levels are observed in rat olfactory bulb upon 
olfactory deprivation (Philpot et al., 1997). In schizophrenia subjects, PV mRNA expression 
(Fung et al., 2010; Hashimoto et al., 2008; Hashimoto et al., 2003; Mellios et al., 2009) and 
bouton PV levels (Glausier et al., 2014) are reduced in the PFC, and we report here that bouton 
CB protein levels are also lower (5.0). Moreover, GAD65 protein levels are reduced under 
conditions of chronic network inactivity (Hartman et al., 2006). In the primary auditory cortex of 
schizophrenia subjects, bouton GAD65 protein levels are reduced and correlate with a lower 
density of dendritic spines in layer deep 3 (Moyer et al., 2012). Similarly, we found that bouton 
levels of GAD65 protein are significantly lower in the PFC of schizophrenia subjects (Appendix 
F Figure F.1). Consistent with this finding, GAD65 protein levels are significantly lower in 
boutons from CB and CR neurons (Appendix F Figure F.2). Although GAD65 mRNA and total 
gray matter GAD65 protein expression, and GAD65 levels in PV basket cell boutons in PFC layer 
deep 3 were previously reported to be unchanged in the PFC of schizophrenia (Guidotti et al., 
2000; Hashimoto et al., 2008; Impagnatiello et al., 1998), GAD65 mRNA and total gray matter 
protein expression is lower in the PFC of subjects diagnosed with schizoaffective disorder 
(Glausier et al., 2015). Our findings of lower bouton GAD65 levels were not a consequence of 
schizoaffective diagnosis (Appendix F Figure F.1), suggesting that within boutons lower 
GAD65 protein levels accompany lower GAD67 levels, at least for some GABA neuron subtypes.  
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 GABA receptors are also responsive to activity-dependent network changes. For example, 
decreased activity in cultured visual cortex and hippocampal neurons results in reduced amplitude 
of miniature inhibitory postsynaptic currents, which is associated with reductions in the number 
of detectable GABA A receptors and lower protein levels of membrane-bound GABA A receptors 
(Kilman et al., 2002; Swanwick et al., 2006). In schizophrenia, lower mRNA expression for the 
α1 and α5 subunits of the GABA A receptor, and lower protein levels for the 1a subtype of the 
GABA B receptor are reported in the PFC (Beneyto et al., 2011; Duncan et al., 2010; Glausier 
and Lewis, 2011; Ishikawa et al., 2005).  
6.3 FUNCTIONAL IMPLICATIONS OF LOWER BOUTON GAD67 PROTEIN 
LEVELS IN GABA NEURON SUBTYPES IN THE PREFRONTAL CORTEX OF 
SCHIZOPHRENIA 
6.3.1 Chandelier cells 
Although GAD67 protein levels in boutons from chandelier cells are trending lower in 
schizophrenia, downregulation of GAT1, which appears to be specific to chandelier cell boutons 
(Woo et al., 1998), may enhance their signaling effects rather than compensate for reduced 
GABA signaling as previously hypothesized (Volk et al., 2002). For example, pharmacological 
blockade of GAT1 increases the latency of postsynaptic responses upon GABA release at rat 
hippocampal synapses (Overstreet and Westbrook, 2003). Considering that GAD67 protein levels 
are only trending lower, vGAT protein levels are unaltered, and GAT1 levels are significantly 
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reduced at some chandelier cell inputs, similar effects may occur at chandelier cell synapses in the 
illness. 
 PV neurons, including chandelier cells, are critically involved in the generation and 
maintenance of gamma-frequency oscillations (Cardin et al., 2009; Fuchs et al., 2007; Sohal et al., 
2009) and altered inhibitory signaling from chandelier cells is hypothesized to contribute to 
altered gamma synchrony; however, signaling from chandelier cells may enhance pyramidal cell 
excitability (reviewed in Lewis, 2011). The postsynaptic responses from chandelier cells are 
highly responsive to network activity. While the synaptic effects of chandelier cells appear to be 
mainly inhibitory under physiological conditions (Woodruff et al., 2011), multiple studies have 
reported that they can also depolarize cortical and hippocampal pyramidal cells (Molnar et al., 
2008; Sauer et al., 2012; Szabadics et al., 2006; Woodruff et al., 2011). The effects from 
chandelier cell inputs are hyperpolarizing when the state of the network is highly active and 
depolarizing when the network is relatively quiescent (Woodruff et al., 2011). Considering that 
activity within the PFC is reduced in schizophrenia (Minzenberg et al., 2009) signaling from 
chandelier cells may favor depolarizing responses. 
6.3.2 CB neurons 
CB/SST neurons regulate the integration of cortico-cortical and thalamo-cortical excitatory 
projections to pyramidal cells (Kapfer et al., 2007; Lovett-Barron et al., 2012; Xu et al., 2013), 
and provide a layer of tonic inhibition via activation of GABA B receptors over the cortical 
network (Urban-Ciecko et al., 2015). Reductions in the strength of signaling from CB neurons 
may increase the gain of local pyramidal cells in the PFC of schizophrenia. Indeed, suppressing 
the activity of SST neurons using optogenetic techniques increases the overall excitability of the 
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network (Urban-Ciecko et al., 2015). Consistent with reduced GABA signaling from CB neurons, 
protein levels for GABA B receptor subunits are reduced in the PFC (Ishikawa et al., 2005) as 
well as mRNA expression for α5-containing GABA A receptors (Beneyto et al., 2011), which are 
enriched at synapses from SST neurons (Ali and Thomson, 2008; Serwanski et al., 2006).  
6.3.3 CR neurons 
In contrast to CB neurons, lower GABA signaling from CR/VIP neurons would presumably 
decrease the activity of the PFC. By predominantly innervating the dendrites and soma of GABA 
neurons (Melchitzky et al., 2005; Melchitzky and Lewis, 2008), the majority of which are SST 
neurons (Pfeffer et al., 2013), CR neurons mediate disinhibitory control of pyramidal cells, and 
thereby control the overall gain within the PFC (Pi et al., 2013). Reduced signaling from CR 
neurons would therefore result in less inhibition of CB neurons and, in turn, reduce the 
excitability of pyramidal cells. 
Activity of CR/VIP neurons has been shown to be important for a number of sensory and 
cognitive processes. For example, selective activation of VIP neurons by optogenetic techniques 
in mice increases the efficiency of tone discrimination in the auditory cortex during an auditory 
discrimination task (Pi et al., 2013). Locomotion induced activation of VIP neurons in mouse 
primary visual cortex enhances visual responses (Fu et al., 2014), and activation of VIP neurons 
via afferents from motor cortex silences SST neurons, and to a lesser extent PV cells, in 
somatosensory cortex during active whisking, which increases the efficacy of sensory responses 
in this brain region (Lee et al., 2013). Moreover, VIP neuron inhibition of PV cells in mouse 
hippocampus modulates learning induced synaptic plasticity during a fear-conditioning paradigm 
(Donato et al., 2013).  
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 Impairments in many of these sensory and cognitive modalities are disrupted in 
schizophrenia. For example, schizophrenia subjects exhibit deficits in tone discrimination 
(Holcomb et al., 1995; Strous et al., 1995), mismatch negativity (Javitt, 2000), and speech 
prosody, which is the ability to recognize discrete tones associated with a wide range of emotional 
states (Leitman et al., 2010). Deficits in orientation surround suppression are reported in the 
illness (Yoon et al., 2009), and correlate with lower GABA levels in the visual cortex (Yoon et 
al., 2010). In monkey, CR neurons receive excitatory projections from brain regions that are 
functionally similar. For example, CR neurons in PFC area 9 receive afferent projections from 
pyramidal cells in PFC area 46 (Medalla and Barbas, 2009), and both brain areas are critically 
involved in working memory tasks (Levy and Goldman-Rakic, 1999; Petrides, 2000; Tanila et al., 
1992; Tanji and Hoshi, 2008). By disinhibiting pyramidal cells CR neurons increase the efficacy 
of excitatory inputs between nearby brain areas that perform similar functions. Altered activity of 
the PFC is widely reported in schizophrenia subjects during cognitive control tasks (Berman et 
al., 1986; Glahn et al., 2005; Minzenberg et al., 2009; Perlstein et al., 2003; Weinberger et al., 
1988; Weinberger et al., 1986), and reduced strength of signaling from CR neurons may result in 
weaker recruitment of neural networks involved in similar cognitive processes. 
6.4 EXPERIMENTAL CONSIDERATIONS 
6.4.1 Data segmentation 
Because previous findings suggested that levels of some proteins are significantly lower in the 
PFC of schizophrenia subjects (i.e. GAD67), the methods used here to assess bouton density and 
 111 
bouton protein content were done to maximize the detectability of immunoreactive objects. This 
approach included using optimal image capture settings for each image acquisition (2.4.2) and 
applying an optimal initial threshold value for data segmentation for each image stack (2.5.2). 
Importantly, the same parameters were used to determine the optimal initial threshold value. 
There are several advantages of using this approach. For example, there is a greater chance of 
under- or over-exposing image stacks, which may result in an underestimate of immunoreactive 
objects or saturated pixels, respectively, when using constant rather than optimal exposure 
settings. Applying an optimal initial threshold value for data segmentation for each image stack 
maximizes the detectability of immunoreactive objects across image stacks with variable intensity 
levels, which can arise from several factors including differences in protein content across cortical 
layers and differences in the density of immunoreactive objects. Because using a consistent way 
of determining an optimal initial threshold value maintains a constant level of sensitivity across 
image stacks, a lower density of objects is attributable to undetectable immunoreactivity, and 
lower intensity levels are due to less protein content in the detectable objects. By contrast, when 
using a constant initial threshold value only objects with relatively similar intensity levels are 
detectable, and therefore changes in intensity levels between conditions may not be found if the 
threshold value used to define the objects is too high; however, if protein content in these objects 
were in fact different between conditions (e.g. schizophrenia and comparison subjects) despite a 
change in intensity levels between the detectable objects, the density of objects would presumably 
be different. A caveat to using an optimal initial threshold value for each stack is that lower 
protein content (e.g. GAD67 protein levels between schizophrenia and comparison subjects) can 
theoretically result in a much lower threshold value and, in turn, a higher density of objects, 
which may include false positives. However, this did not appear to be the case for our data 
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segmentation procedure since bouton GAD67 protein levels and the density of vGAT+/GAD67-
IR boutons were significantly lower in schizophrenia subjects (3.0), and since the density of 
CB+/vGAT+/GAD67+ boutons and CR+/vGAT+/GAD67+ boutons were unchanged and 
significantly lower, respectively, even though both bouton subtypes had significantly lower 
GAD67 protein levels (5.0). 
6.4.2 Other microscopy techniques for assessing synaptic protein levels 
In contrast to protein immunoblotting techniques (i.e. Western blot), which typically require 
tissue homogenates, the confocal microscopy techniques used here allowed for the simultaneous 
detection of multiple proteins within axonal boutons. The colocalization of vGAT and GAD67 
presumably designated presynaptic terminals; though, it is unknown if all of these boutons were 
truly presynaptic to postsynaptic elements. Additional techniques which provide a significant 
increase in the resolving power of neuronal structures within tissue sections or an increase in the 
number of synaptic proteins that can be assessed may be used to quantify the proteins assessed 
here that are specifically apposed to postsynaptic structures. For example, studies using electron 
microscopy (EM) provide the highest level of resolution for assessing neuronal ultrastructure 
including synapses in postmortem tissue sections. With EM techniques, multiple proteins can be 
simultaneously quantified within presynaptic terminals using different size metallic nanoparticles; 
however, multi-label EM studies are currently able to only reliable differentiate ~2 specific 
proteins (Bleher et al., 2008). Other microscopy techniques provide the same image resolution 
used here but allow for the detection of a greater number of proteins. For example, with array 
tomography, multiple proteins within serial ultrathin tissue sections can be labeled, imaged, and 
then removed, and a new set of several other proteins can be labeled and imaged within the same 
 113 
tissue section (Micheva and Smith, 2007). The images containing the different labeled proteins 
can then be collated and aligned. Therefore, multiple apposed presynaptic and postsynaptic 
proteins can be simultaneously quantified within the same tissue sections. Moving forward, 
studies using other techniques than those used here, such as EM and array tomography will be 
important for testing the reproducibility of our results and for simultaneously assessing a greater 
number of pre- and postsynaptic proteins involved in GABA signaling in schizophrenia. 
6.5 SUMMARY 
This dissertation provides the first direct assessment of GAD67 expression levels in chandelier, 
CB, and CR neurons in schizophrenia with the goal of identifying which subtypes are affected by 
lower bouton GAD67 protein levels. First, we determined that reduced GAD67 mRNA 
expression in only a subset of neurons in the PFC of schizophrenia subjects is associated with 
lower GAD67 protein levels in only a subset of axonal boutons (3.0). Investigation of GAD67 
protein levels within GABA neuron subtypes found that GAD67 levels in boutons from 
chandelier cells were only trending lower in schizophrenia (4.0). By contrast, boutons from CB 
neurons had significantly lower GAD67 levels. Some boutons arising from CR neurons lacked 
detectable GAD67 protein levels, and GAD67 levels were significantly lower in the CR boutons 
that contained GAD67 (5.0). These findings suggest that lower GAD67 expression in the PFC of 
schizophrenia subjects is not restricted to a specific subtype of GABA neuron, but rather lower 
GAD67 expression affects a proportion of several subtypes, which may be a consequence of 
lower PFC activity. GABA neurons play unique functional roles within cortical networks and 
these findings shed light on the pathophysiological changes in the PFC of schizophrenia subjects. 
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APPENDIX A 
 
 
Figure A.1. PV neurons are distinguishable by their GAD65 and GAD67 mRNA content. Single plane image of 
a human PFC tissue section labeled for GAD65, GAD67, and PV mRNAs, and counterstained with NeuroTrace. 
Single channel images of lipofuscin autofluorescence (A, A’), GAD65 mRNA (B, B’), GAD67 mRNA (C, C’), PV 
mRNA (D, D’), and NeuroTrace (E, E’). (F, F’) Merged channels image of B (B’), C (C’), and E (E’). (A-F) Arrows 
depict a GAD65/GAD67 mRNA expressing neuron (arrow) and a GAD67/PV mRNA expressing neuron (solid 
arrowhead). The open arrowheads in A and B identify lipofuscin autofluorescence in the GAD67/PV mRNA 
expressing neuron. (A’-F’) Neuron expressing GAD65/GAD67/PV mRNA. Bar = 10 μm. 
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APPENDIX B 
CHAPTER 2 SUPPLEMENTAL MATERIALS 
B.1 SUPPLEMENTAL METHODS 
Table B.1. Detailed demographic and postmortem characteristics of human subjects. aPMI, postmortem interval 
(hours); bYears stored in 30% glycerin/30% ethylene glycol solution at -30°C. Abbreviations: M, male; F, female; W, 
white; B, black; ASCVD, arteriosclerotic cardiovascular disease; AAR, alcohol abuse, in remission at time of death; 
ADC, alcohol dependence, current at time of death; ADR, alcohol dependence, in remission at time of death; OAR, 
ATOD, at time of death; CO, carbon monoxide; U, unknown. 
 
 
 
 
Healthy Comparison Subjects Subjects with Schizophrenia
Pair Case Sex/ Race
Age 
(years) PMIa
Storage 
Timeb
Cause of 
Death Case DSM IV diagnosis
Sex/  
Race
Age 
(years) PMIa
Storage 
Timeb Cause of Death
Antipsychotic 
ATOD 
Antidepressant 
ATOD
Benzodiazepine/ 
Anticonvulsant 
ATOD
Nicotine Use 
ATOD
1 727 M/B 19 7.00 12.90 Trauma 829 Schizoaffective disorder; ADC; OAR M/W 25 5.00 11.34
Suicide by 
salicylate overdose N N Y Y
2 852 M/W 54 8.00 10.90 Cardiac tamponade 781
Schizoaffective disorder; 
ADR M/B 52 8.00 12.16 Peritonitis Y Y N Y
3 1307 M/B 32 4.80 5.20 ASCVD 10024 Paranoid schizophrenia M/B 37 5.98 5.96 ASCVD N N N N
4 567 F/W 46 15.00 14.80 Mitral valve prolapse 537 Schizoaffective disorder F/W 37 14.50 15.25 Suicide by hanging N N N U
5 1047 M/W 43 13.80 8.10 ASCVD 1209 Schizoaffective disorder M/W 35 9.1 6.50
Suicide by 
diphenhydramine 
overdose
Y N N N
6 739 M/W 40 15.8 13 ASCVD 933 Disorganized schizophrenia M/W 44 8.30 9.66 Myocarditis Y Y Y N
7 451 M/W 48 12.00 16.30 ASCVD 317 Chronic undifferentiated schizophrenia M/W 48 8.30 18.9 Bronchopneumonia Y Y N N
8 178 M/W 48 7.80 20.50 ASCVD 377 Chronic undifferentiated schizophrenia M/W 52 10.00 18.1
Gastrointestinal 
bleeding Y N N N
9 452 F/W 40 14.30 16.30 ASCVD 341 Chronic undifferentiated schizophrenia F/W 47 14.50 18.6
Suicide, 
chlorpromazine 
overdose
Y N N Y
10 449 F/W 47 4.30 16.30 Accidental CO poisoning 517
Chronic disorganized 
schizophrenia F/W 48 3.70 15.10
Intracerebral 
hemorrhage Y N N Y
11 681 M/W 51 11.60 14.10 Hypertrophic cardiomyopathy 234
Chronic paranoid 
schizphrenia M/W 51 12.80 21.00 Cardiomyopathy N N N N
12 395 M/W 42 12.30 18.80 Pericardial tamponade 322
Chronic undifferentiated 
schizophrenia M/W 40 8.50 20.20
Suicide, combined 
drug overdose Y Y N N
13 575 F/B 55 11.30 15.40 ASCVD 597 Schizoaffective disorder F/W 46 10.10 15.1 Pneumonia Y Y N Y
14 278 M/W 50 4.50 20.40 ASCVD 640 Chronic paranoid schizphrenia M/W 49 5.20 14.5
Pulmonary 
Embolism Y Y N U
15 1284 M/W 55 6.40 5.60 ASCVD 1105 Schizoaffective disorder M/W 53 7.90 7.47 ASCVD Y N N Y
16 1122 M/W 55 15.40 7.30 Cardiac Tamponade 930
Disorganized 
schizophrenia; ADR; OAR M/W 47 15.30 9.70 ASCVD Y N Y Y
17 250 F/W 47 5.30 19.70 ASCVD 398 Schizoaffective disorder F/W 41 10.30 17.7 Pulmonary embolus Y N Y U
18 412 M/W 42 14.20 17.50 Aortic stenosis 422 Chronic paranoid schizphrenia M/W 54 11.00 17.20 ASCVD Y N Y U
19 344 M/W 50 6.80 18.60 ASCVD 1296 Undifferentiated schizophrenia M/W 48 7.80 5.42 Pneumonia Y Y N Y
20 1391 F/W 51 7.8 4 ASCVD 1189 Schizoaffective disorder; AAR F/W 47 14.4 7
Suicide by 
combined drug 
overdose
Y Y Y Y
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APPENDIX C 
CHAPTER 3 SUPPLEMENTAL MATERIALS 
C.1 SUPPLEMENTAL RESULTS 
 
 
Figure C.1. vGAT+/GAD67-IR bouton vGAT protein levels. vGAT protein levels per bouton in total gray matter. 
The data points in each scatterplot represent a matched pair of schizophrenia (sz) and comparison (cntl) subject. 
Points below the unity line reflect pairs in which the measures are lower for the schizophrenia relative to the 
comparison subject. 
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APPENDIX D 
CHAPTER 4 SUPPLEMENTAL MATERIALS 
D.1 SUPPLEMENTAL RESULTS 
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Figure D.1. Examples of vGAT+/GAD67+ and vGAT+/GAD65+/GAD67+ boutons. Projection image (3 z-planes 
taken 0.25 μm apart) of a human PFC tissue section immunolabeled for vGAT, GAD65, and GAD67. Single channel 
images of (A) GAD65, (B) GAD67, (C) vGAT, and (D) lipofuscin autofluorescence. (E) Merged image of A, B, and 
C. (F) Object masks corresponding to A, B, and C. Arrows indicate vGAT+/GAD67+ (arrowheads) and 
vGAT+/GAD65+/GAD67+ (arrows) boutons. Bar = 10 μm. 
 
 119 
 
 
Figure D.2. Effects of potential comorbid factors on the density and levels of GAD67 from vGAT+/GAD67+ 
boutons in schizophrenia. The number of schizophrenia subjects in each comparison group is indicated at the top of 
each graph. Bolded values indicate significant differences between groups. ATOD, at time of death; benz/val; 
benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
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Figure D.3. Effects of potential comorbid factors on the density and levels of GAD67 from 
vGAT+/GAD65+/GAD67+ boutons in schizophrenia. The number of schizophrenia subjects in each comparison 
group is indicated at the top of each graph. Bolded values indicate significant differences between groups. ATOD, at 
time of death; benz/val; benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
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Figure E.1. CB+/vGAT+/GAD67+ and CB+/vGAT+/GAD65+/GAD67+ bouton vGAT protein levels between 
diagnostic groups. Mean vGAT protein levels in CB+/vGAT+/GAD67+ (A) and CB+/vGAT+/GAD65+/GAD67+ 
(B) boutons in total gray matter. 
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Figure E.2. Effects of potential comorbid factors on levels of GAD67 and CB from CB+/vGAT+/GAD67+ 
boutons in schizophrenia. The number of schizophrenia subjects in each comparison group is indicated at the top of 
each graph. Bolded values indicate significant differences between groups. ATOD, at time of death; benz/val; 
benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
 
 123 
 
 
Figure E.3. Effects of potential comorbid factors on levels of GAD67 and CB from 
CB+/vGAT+/GAD65+/GAD67+ boutons in schizophrenia. The number of schizophrenia subjects in each 
comparison group is indicated at the top of each graph. Bolded values indicate significant differences between 
groups. ATOD, at time of death; benz/val; benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
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Figure E.4. CR+/vGAT+/GAD67-, CR+/vGAT+/GAD65+, and CR+/vGAT+/GAD65-IR bouton density 
between diagnostic groups. Mean density of CR+/vGAT+ boutons that lacked GAD65 and/or GAD67 
immunoreactivity (CR+/vGAT+/GAD-; A), CR+/vGAT+/GAD65+ boutons (B), and all CR+/vGAT+ boutons that 
contained GAD65 immunoreactivity (i.e. CR+/vGAT+/GAD65+ and CR+/vGAT+/GAD65+/GAD67+ boutons; 
CR+/vGAT+/GAD65-IR; C) in total gray matter. 
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Figure E.5. CR+/vGAT+/GAD67+ and CR+/vGAT+/GAD65+/GAD67+ bouton vGAT protein levels between 
diagnostic groups. Mean vGAT protein levels in CR+/vGAT+/GAD67+ (A) and CR+/vGAT+/GAD65+/GAD67+ 
(B) boutons in total gray matter. 
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Figure E.6. Effects of potential comorbid factors on the density and levels of GAD67 from 
CR+/vGAT+/GAD67+ boutons in schizophrenia. The number of schizophrenia subjects in each comparison group 
is indicated at the top of each graph. Bolded values indicate significant differences between groups. ATOD, at time of 
death; benz/val; benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
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Figure E.7. Effects of potential comorbid factors on the density and levels of GAD67 from 
CR+/vGAT+/GAD65+/GAD67+ boutons in schizophrenia. The number of schizophrenia subjects in each 
comparison group is indicated at the top of each graph. Bolded values indicate significant differences between 
groups. ATOD, at time of death; benz/val; benzodiazepines/valproic acid; SAD, schizoaffective disorder. 
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Figure F.1. vGAT+/GAD65+ and vGAT+/GAD65+/GAD67+ bouton GAD65 protein levels between diagnostic 
groups and effects of schizoaffective diagnosis. Mean GAD65 protein levels in vGAT+/GAD65+ (A1) and 
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vGAT+/GAD65+/GAD67+ (A2) boutons between schizophrenia (sz) and comparison (cntl) subjects in total gray 
matter. Mean GAD65 protein levels in vGAT+/GAD65+ (B1) and vGAT+/GAD65+/GAD67+ (B2) boutons between 
schizophrenia subjects and subjects diagnosed with schizoaffective disorder (SAD). 
 
 
 
 
 
Figure F.2. CB bouton and CR bouton GAD65 protein levels between diagnostic groups. Mean GAD65 protein 
levels in vGAT+/GAD65+ boutons (A1 and B1) and vGAT+/GAD65+/GAD67+ boutons (A2 and B2) from CB 
neurons (A) and CR neurons (B) in total gray matter. 
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